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Abstract
The integration of gene therapy into tissue engineering to control differentiation and direct tissue 
formation is not a new concept; however, successful delivery of nucleic acids into primary cells, 
progenitor cells, and stem cells has proven exceptionally challenging. Viral vectors are generally 
highly effective at delivering nucleic acids to a variety of cell populations, both dividing and non-
dividing, yet these viral vectors are marred by significant safety concerns. Non-viral vectors are 
preferred for gene therapy, despite lower transfection efficiencies, and possess many customizable 
attributes that are desirable for tissue engineering applications. However, there is no single non-
viral gene delivery strategy that “fits-all” cell types and tissues. Thus, there is a compelling 
opportunity to examine different non-viral vectors, especially physical vectors, and compare their 
relative degrees of success. This review examines the advantages and disadvantages of physical 
non-viral methods (i.e., microinjection, ballistic gene delivery, electroporation, sonoporation, laser 
irradiation, magnetofection, and electric field-induced molecular vibration), with particular 
attention given to electroporation because of its versatility, with further special emphasis on 
Nucleofection™. In addition, attributes of cellular character that can be used to improve 
differentiation strategies are examined for tissue engineering applications. Ultimately, 
electroporation exhibits a high transfection efficiency in many cell types, which is highly desirable 
for tissue engineering applications, but electroporation and other physical non-viral gene delivery 
methods are still limited by poor cell viability. Overcoming the challenge of poor cell viability in 
highly efficient physical non-viral techniques is the key to using gene delivery to enhance tissue 
engineering applications.
INTRODUCTION
Combining tissue engineering and gene therapy for clinical applications is not a new idea; 
however, figuring out how to successfully integrate them has proven to be a major challenge. 
Both tissue engineering and gene therapy strategies endeavor to treat degenerative diseases, 
cancers, trauma, and tissue defects that compromise the functions of organs.106 However, 
both groups of strategies seem to utilize opposing methodologies. From a broad perspective, 
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most tissue engineering strategies attempt to manipulate cellular behavior from an “outside-
in” approach by varying cellular interactions with biomaterials, growth factors, and 
mechanical stimuli.90 Conversely, gene therapy strategies attempt to control cellular 
behavior through an “inside-out” approach by directly delivering nucleic acids (i.e., DNA, 
siRNA, shRNA, miRNA, and antisense oligonucleotides) into cells to trigger or stall gene 
expression.151, 156 Several tissue engineering strategies utilize progenitor cells or stem cells 
to regenerate damaged tissues by seeding cells into biomaterial scaffolds.183 The culture 
conditions, type of biomaterial, and mechanical stimuli can be used to direct progenitor and 
stem cells toward a specific lineage. Additionally, growth factors have been added to cell 
culture medium or encapsulated for controlled release from biomaterial scaffolds to promote 
cell differentiation.40, 95, 100, 105 However, growth factors can be costly and exhibit short 
half-lives.133 Furthermore, once growth factors are deposited into cell culture or into 
extracellular matrices (ECM), there is no way to control how the growth factors will disperse 
and interact with cells, meaning that not all cells may interact with the growth factors 
uniformly or at all. Hence, a strategy where cells could produce, express, and control growth 
factors needed for differentiation would be beneficial for tissue engineering.
Gene therapy has been investigated as a potential solution to overcome the challenges 
associated with using growth factors by delivering DNA to induce gene expression or 
delivering siRNA, shRNA, miRNA, or antisense oligonucleotides to knockdown gene 
expression; however, gene therapy has its own set of unique challenges.33, 67, 77, 81, 171 
Nucleic acids have proven difficult to deliver to a variety of primary cells, progenitor cells, 
and stem cells, and the ability to manipulate gene expression in targeted cells has proven 
challenging as well.28
The difficulty behind achieving successful transfection is due in part to the many barriers a 
delivery vector must overcome to gain access to the cellular membrane, cytoplasmic 
compartment, and interior of the nucleus before target genes can be expressed (Figure 1). 
Nucleic acids must first be stabilized in some form to successfully navigate through the 
extracellular environment to avoid undergoing degradation from changes in pH, exposure to 
proteases and nucleases, and opsonization.1 After navigating through the extracellular 
environment to the target cell, nucleic acids must properly associate with the cell membrane 
and cross the plasma membrane via penetration, electrostatic interaction, adsorption, or 
ligand mediated receptor binding.38, 66, 88, 120, 148, 150, 157, 178, 188, 201 Both Mercer et al.109 
and Conner et al.30 have extensively reviewed cell entry methods through various 
endocytotic pathways. Once the nucleic acids reach the cytoplasmic compartment, nucleic 
acids must avoid degradation by endocytotic mechanisms and cytoplasmic nucleases.86 If a 
nucleic acid enters the cell through an endocytotic mechanism, the complex must 
successfully escape the endosome before undergoing degradation by a lysosome or before 
the endosome is recycled back to the cell surface.4, 192, 204 Once the nucleic acid has 
escaped the endosome, it must avoid degradation while trafficking through the highly 
crowded cell cytoplasm, which slows the diffusion of DNA to less than 1% of its rate in 
water.103 RNA complexes and antisense oligonucleotides only need to reach mRNAs located 
in the cell cytoplasm; however, DNA complexes must cross the nuclear envelope before 
transcription can occur. We refer the reader to Merdan et al.110, who have provided a 
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comprehensive review on the “barriers” that polymeric gene delivery vectors must 
overcome.
A variety of methods have been engineered to overcome the barriers to gene delivery, but 
each of these methods have their own unique advantages and disadvantages. Viral vectors 
have proven to be the most efficient and effective gene delivery method, and the benefits of 
viral vectors have been reviewed in depth by Kay et al.82 and Zhang et al.205. However, there 
are major concerns regarding the safety of viral vectors such as toxicity, immunogenicity, 
and oncogenesis from insertional mutagenesis.24, 176 Furthermore, viral vectors possess 
restricted sequence sizes, and viral vectors can be laborious and costly to engineer. Viral 
vectors may possess innate tropisms to specific cell types or cell-selective promoters, which 
may limit their effectiveness in other cell populations.181
Non-viral methods are able to circumvent most of the concerns associated with viral gene 
delivery methods. However, non-viral methods exhibit lower delivery efficacies than viral 
gene delivery methods. Non-viral gene delivery methods can be broadly separated into 
chemical and physical approaches. Chemical approaches utilize cationic lipids, cationic 
polymers, and cell-penetrating peptides that can be engineered to target specific cells locally 
or systemically.11–13, 87 Chemical vectors avoid some safety concerns associated with 
disease-causing viral vehicles; however, effective doses of chemical vectors can be toxic, 
especially to sensitive cell populations because large doses are required to overcome the 
poor efficiency.187 Chemical approaches seem to be most effective at targeting cancer cells 
in vitro and in vivo, and chemical vectors can be customized for specific tissue engineering 
applications; however, primary cells, progenitor cells, and stem cells have proven more 
difficult to transfect with chemical vectors. Despite the difficulty in transfecting primary 
cells, progenitor cells, and stem cells, there has been considerable enthusiasm for the further 
improvement of chemical vectors for the hope of one day achieving efficacies and 
efficiencies that could potentially mimic viral vectors.51, 52, 61, 78, 110, 112, 113, 132
Chemical vectors face many challenges and obstacles because chemical vectors must 
overcome all of the previously stated barriers. Physical methods, on the other hand, have 
been shown to be effective at transfecting primary cells, progenitor cells, and stem cells 
through in vitro, ex vivo, and in vivo approaches.108 This effectiveness may be in part due to 
the fact that physical approaches attempt to directly force nucleic acids into the cytoplasmic 
compartment or nucleus to achieve successful transfection. However, physical delivery 
methods face different limitations than chemical delivery methods. Depending on the 
physical delivery method used, the cell may sustain heavy trauma and initiate apoptotic or 
programmed cell death mechanisms. Thus, physical gene delivery strategies tend to exhibit 
lower cell viabilities and there is risk that the physical invasion may cause cells to senesce, 
which could negatively influence cell phenotype. Hence, a major obstacle that limits 
physical gene delivery in tissue engineering applications is low cell viability.
Over the last decade, significant improvements have been made in areas of microinjection, 
ballistic gene delivery, electroporation, sonoporation, and laser irradiation, presenting a 
refreshing opportunity for using non-viral vectors for tissue engineering applications. 
Nonetheless, different non-viral physical vectors are successful in different cell types. Thus, 
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there is a need to examine which attributes of different non-viral physical vectors enable 
successful transfection and which physical characteristics of cells enable the ability of the 
cell to survive the transfection. Comparing the attributes of successful transfection 
techniques with characteristics of difficult-to-transfect cells that survive transfection 
methods may provide insight into physical details between the delivery vector and cell that 
may lead to more efficient gene delivery strategies for tissue engineering applications.
Hence, the goal of this review is to examine the advantages and disadvantages of non-viral 
physical vectors (i.e., microinjection, ballistic gene delivery, electroporation, sonoporation, 
laser irradiation, and lesser-known methods such as magnetofection and electric field-
induced molecular vibration), with special attention given to electroporation because of its 
versatility. An additional goal of this review is to identify the physical characteristics of cells 
that survive and successfully express the target gene for the purpose of determining which 
physical features between delivery vector and cell type can be used to enhance 
differentiation strategies for tissue engineering applications.
PHYSICAL GENE DELIVERY STRATEGIES
While much attention has been given to viral and chemical non-viral delivery systems for 
transporting nucleic acids into cells, physical non-viral gene delivery methodologies have 
shown promise for transfecting difficult-to-transfect cells. Physical gene delivery methods 
attempt to deliver nucleic acids directly to the cell, and attempt to avoid complications 
associated with targeting, endocytotic pathways and immunogenicity.89 However, physical 
gene delivery has its own set of advantages and disadvantages, which limits its use for 
certain applications. Microinjection is a technique that directly delivers DNA to the cell 
nucleus, whereas ballistic gene delivery uses a projectile to deliver DNA to the cell. 
Electroporation utilizes electrical potentials to induce the formation of pores in the cell 
membrane while sonoporation utilizes physical disturbances in the fluid to induce pores in 
the cell membrane for nucleic acid delivery. Laser irradiation perforates individual cells by 
focusing a laser beam on a localized area of the cell membrane to enable the entry of nucleic 
acids. Nonetheless, physical gene delivery has been favorable for tissue engineering 
applications where ex vivo approaches can be utilized. In the following sections, this review 
highlights some of the advantages and disadvantages of the most common (and uncommon) 
physical gene delivery methods from a tissue engineering perspective, provide examples of 
how physical gene delivery has been integrated into tissue engineering, and examine 
challenges that still need to be addressed to further improve the integration of gene therapy 
and tissue engineering.
MICROINJECTION
Microinjection is perhaps the most direct nucleic acid delivery method of all of the physical 
delivery methods. The development of microneedles and the applications for which they can 
be used have expanded considerably over the past 30 years. Prausnitz et al.144, 146 have 
published excellent reviews regarding the evolution of microneedles for drug delivery 
applications and developing gene vaccines. Microneedles are no longer confined to the 
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toolbox of cell biologists, but now are widely used by pharmaceutical manufacturers and are 
gaining popularity among bioengineers.
In their earliest form, microneedles were made of glass and used to inject nucleic acids 
directly into cellular cytoplasm and nuclei as illustrated in Figure 2A.193 Microinjection of 
nucleic acids became a robust method to transfect cells with specific amounts of pure 
nucleic acids.92 However, the technique proved to be tedious, and no more than a few 
hundred cells at best could be transfected using this method. Despite the difficulties 
associated with microinjection, the technique persisted, and became quite valuable among 
cellular biologists for studying RNA trafficking,135 immunocytochemistry,94 and making 
transgenic animals.9, 27, 32 Specifically, the ability to create transgenic animals became a 
powerful tool for illuminating functions of uncharacterized genes. Dahlhoff et al.32 
successfully created transgenic mice that express Cre recombinase in pancreatic B-cells by 
using pronuclear microinjection in C57BL fertilized oocytes. Today, single microneedles are 
used for transfecting rat and mouse ova for creating transgenic animals and for facilitating 
somatic nuclear transfer.
Beyond creating transgenic animals, microneedles are used for transdermal delivery of 
nucleic acids and drugs.39 Microneedles can be arranged in arrays, which have proven to be 
advantageous for transdermal drug delivery as microneedles can penetrate the outer layer of 
the skin and the stratum corneum, and deliver drugs, nucleic acids, and macromolecules 
directly to the epidermis by creating microchannels in the stratum corneum.134 Furthermore, 
microneedles can be easily fabricated and engineered to accommodate multiple delivery 
applications. For example, microneedles can be manufactured from silicon, metal, or 
biodegradable polymers.131 As such, the size and shape of microneedles can be easily 
modified for drug delivery applications. Microneedles can be made hollow to be used as an 
injectable vehicle, or microneedles can be made solid and coated with drug or nucleic acid 
for direct application to tissue as illustrated in Figure 2B and Figure 2C.50, 159 Gill et al.50 
found that microneedles could be coated with microparticles containing a diameter no bigger 
than 10 μm, and successfully delivered payloads to the stratum corneum without wiping off 
on the skin. In addition, Choi et al.26 and Daugimont et al.34 have published exciting 
investigations on combining electroporation techniques with microinjection techniques for 
the purpose of creating DNA vaccinations delivered through the skin.
However, despite the benefits of microinjection, there are still limitations to the use of 
microinjection for tissue engineering. The use of single microneedles is highly inefficient for 
most tissue engineering applications, as typically the transfection of cells is needed on a 
larger scale than a few hundred cells and on multiple overlapping cell layers. Additionally, 
rat and mouse ova are large cells that can accommodate microneedles, whereas some smaller 
cells such as fibroblasts are much more difficult to transfect with a microneedle. The 
diameter of the pipette tip and timing of injection (within the cell cycle) can play a major 
role in the ability of the cell membrane to reseal and survive.182 Thus, a major factor that 
determines the success of the technique is the technical ability of the individual injecting the 
cells. Furthermore, when microneedles are used in an array format, care must be taken to 
ensure that the stiffness of the microneedles are strong enough to endure the shear forces of 
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the tissue so that the needles do not break and tear the tissue layer or fail to distribute drugs 
or nucleic acids uniformly.
In summary, microneedles are a safe way to deliver nucleic acids to a variety of cell types 
directly, thus avoiding many of the gene delivery barriers mentioned earlier; however, single 
cell transfections are inefficient for most tissue engineering applications. Microinjection 
requires precision and high accuracy for success, which places the majority of the success or 
failure of the technique on ability of the individual performing the technique. The shape, 
size, and location of target cells can greatly restrict the ability of the investigator to 
effectively transfect cells via microinjection as well. Furthermore, isolation and 
immobilization of cells are an additional challenge that requires specialized training for 
successfully transfecting cells via microinjection. Microinjection could be far more attractive 
for tissue engineering if the process of isolating and injecting the cell of interest could be 
automated to remove the “human” factor from the process.
BALLISTIC GENE DELIVERY (GENE GUN)
Interdermal powder injection, biolistics, or ballistic gene delivery are names for a needle-
free gene delivery technique originally developed by Sanford et al.154 to transfect plant cells 
using DNA-coated metal particles. Over the years, the ballistic method was refined and 
commercialized for use in mammalian cells using both DNA and RNA.195 Ballistic gene 
delivery is a needle-free alternative to electroporation and microinjection that allows for 
DNA or RNA to be precipitated onto gold or tungsten particles, ranging in size from the 
nanometer to micron scale. The particles are delivered directly to mammalian tissues as a 
projectile out of a barrel of a pressurized ballistic device, colloquially referred to as a “gene 
gun”. Particles are projected via a helium discharge or high-voltage electric spark, and can 
be propelled directly into the cell cytoplasm or nucleus (Fig. 3). Ballistic gene delivery has 
gained popularity as a potential delivery method for gene vaccines, as the DNA or RNA can 
penetrate the stratum corneum of the skin and reach the epidermis.177 Additionally, 
investigators have successfully transfected mouse skeletal muscle fibers and liver tissue in 
vivo using ballistic gene delivery.203 Zelenin et al.203 transfected skeletal muscle fibers in 
mdx male mice with plasmid DNA expressing human Dystrophin in vivo. Approximately 20 
to 30 μg of the Dystrophin plasmid were precipitated onto gold/tungsten (1:4) particles 
ranging in size from 1 to 4 μm in diameter for each discharge. The DNA coated particles 
were projected onto the tissue from a distance of 10 cm. Immunohistochemistry was used to 
detect the positive expression of human Dystrophin on the skeletal muscle fibers. According 
to Zelenin et al.203 the number of human Dystrophin positive muscle fibers were found to 
vary from 2.5% on day 17 up to 5% on day 60 post-bombardment. The study published by 
Zelenin et al.203 was one of the first studies to demonstrate the ability to deliver reporter and 
therapeutic genes in vivo to skeletal fibers in mdx mice via ballistic gene delivery. 
Furthermore, ballistic gene delivery has become not only a method to deliver therapeutic 
agents, but diagnostic agents as well. Several researchers have used the gene gun to deliver 
fluorescent dyes to track the functions of neurons.15, 85 Thus, ballistic gene delivery has 
continued to grow in popularity as an alternative to microinjection for in vivo applications.
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However, while useful for potential gene vaccine applications, ballistic gene delivery has 
several limitations. Ballistic gene delivery has a limited tissue depth to which DNA 
microparticles can be transmitted, thus many studies have investigated gene delivery to the 
skin. Furthermore, the path of the projectile can cause inflammation and damage to the 
target tissue with improper operation of the gene gun, or if the target tissue is bombarded 
with a high density of microparticles.169 Moreover, ballistic gene delivery lacks cell 
specificity, so non-targeted cells may be transfected with the gene of interest if the non-
targeted cells are within the dispersal area of the gene gun. In addition, microparticles can 
accommodate limited quantities of DNA or RNA. Thus, several treatments are needed to 
transfect a large population of cells if ballistic gene delivery is to be used for tissue 
engineering applications. Furthermore, there is no reliable way to ensure that multiple 
treatments would uniformly distribute DNA microparticles, and not produce an 
inflammatory response in the target tissue. Mitchell et al.116 and Kendall et al.84 explored 
the effects of temperature, distance, and pressure on the penetration of DNA microparticles 
on buccal mucosa and porcine skin, respectively, and both groups found that uncontrolled 
environmental factors can greatly influence the efficacy of using ballistic gene delivery. 
Kendall et al.83 confirmed that gold particles ranging in size from 0.4 to 2.4 μm were able to 
achieve a greater impact velocity (420 – 640 m/s) than glass or polystyrene particles when 
delivered via a contour shock tube (CST). Furthermore, Kendall et al.83 noted that the sizes 
of gold particles are typically smaller than cells allowing for penetration into the cell 
cytoplasm when delivered via ballistic gene delivery. Thus, the physical parameters need to 
be tightly regulated to optimize uniform delivery to cell cultures, which may not be possible 
for in vivo applications.
Thus, in summary, ballistic gene delivery can produce transient gene expression by directly 
delivering DNA to the cell cytoplasm or nucleus; however the delivery of DNA via ballistic 
gene delivery can be quite variable. Ballistic gene delivery is able to transfect primary 
tissues and difficult-to-transfect cells. However, ballistic gene delivery is limited in tissue 
engineering applications, as it can only transfect a limited number of cells, and not always in 
a uniform manner. Despite the drawbacks of ballistic gene delivery, it is an excellent method 
for developing gene vaccines as the DNA microparticles can readily penetrate the stratum 
corneum. As more research is conducted on ballistic gene delivery, perhaps a high 
throughput design will be developed that can consistently maintain precision and accuracy 
for nucleic acid delivery, or use different particle delivery materials to avoid inflammation 
and increase nucleic acid payload.
ELECTROPORATION
One of the most effective non-viral gene delivery methods, which has been extensively used 
and studied is electropermeabilization, also known as DNA electrotransfer, and colloquially 
referred to as “electroporation.” Neumann et al.124 introduced electroporation almost 30 
years ago by successfully transfecting mouse lyoma cells. Since then, electroporation has 
evolved rapidly. In vivo studies have been well underway since 1996, and since then 
electroporation technologies have successfully transfected skin, skeletal muscle, liver, tumor 
tissues in vivo.3, 14, 36, 69, 71 Aihara et al.3 injected the tibialis anterior muscles of C57BL 
mice with 50 μg of plasmid expressing interleukin-5 (Il-5), and electroporated the tissues in 
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vivo using a pair of electrode needles inserted to a depth of 5 mm and separated by 5 mm. A 
square-wave pulse at a frequency of pulse per second lasting no more than 50 ms was 
administered at 100 V. After five days, serum from the mice treated with electroporation 
contained over 20 ng/mL of Il-5, whereas mice only injected with plasmid had serum 
containing 0.2 ng/mL. Furthermore, Heller et al.69 successfully transfected the livers of male 
Sprague-Dawley rats via in vivo electroporation using the luciferase reporter gene. Six 28 
gauge acupuncture needles were used as electrodes and inserted into the right median lobe in 
the pattern of a 1 cm diameter circle so that the electrodes were equidistant from the center 
of the circle, where 100 μg of DNA was injected. Six pulses lasting a duration 99 μs at a 
frequency of 1 pulse per second were administered to create a rotating electric field. 
Approximately 30 to 40% of the rat liver cells that underwent electroporation expressed 
maximum luminescence 48 hours after transfection. Luminescence was detected up to 21 
days after electroporation at 5% of the maximum expression in the electroporated liver cells. 
Both of the studies conducted by Aihara et al.3 and Heller et al.69 were significant because 
both studies were some of the first in vivo studies that demonstrated electroporation could 
deliver genes in vivo successfully. Thus, it is necessary to look at how electroporation is 
thought to work to better understand its potential for tissue engineering. Additionally, this 
review examines a commercial electroporator that has gained much attention to aid in the 
discussion of how electroporation could be used for tissue engineering and cell 
differentiation.
In the broadest sense, electroporation is the application of an electrical field to a cell 
population for a finite amount of time to increase cell permeability to DNA, RNA and small 
proteins by creating localized transient disturbances in the cell membrane.7, 115, 184, 185 
Electroporation has shown to be highly effective in a wide variety of tissues in vivo, and cell 
cultures in vitro. In particular, electroporation has been used to aid chemotherapy for cancer 
treatment.70, 101, 149, 164, 165, 186 In cancer treatments, irreversible electroporation is 
employed to ablate cancer tissues by inducing permanent formation of stable, non-resealing 
pores.123 In gene therapy, reversible electroporation is employed, which keeps tissues intact 
because membrane pores are able to reseal.
There are many excellent reviews, in particular those published by Farvard et al.,45 Teissié et 
al.,174 Cemazar et al.,21 Weaver et al.,185 Mir et al.,114 and Zimmerman et al.208 as well as 
work published by Golzio et al.,56, 57 which collectively explain the physical mechanisms 
proposed to take place during electroporation. To summarize, when an electric field is 
applied across a set of cells, hydrophilic pores are thought to form on the sides of the cell 
facing the electrodes, hence the name “electroporation.”136, 147 However, the precise 
mechanisms by which nucleic acids cross the cell membrane are still under investigation. 
Electrophoresis has been implicated as a possible process for enabling nucleic acids to 
diffuse from the extracellular environment into the intracellular environment during the 
application of the electric field when nucleic acids are tightly associated with the cell 
membrane.191 However, other studies suggest internalization of nucleic acids is restricted to 
nucleic acids bound to the cell membrane.58 In addition to uptake mechanisms, the subject 
of how nucleic acids are transported and trafficked through the cell to the nucleus is still 
widely debated. Wu et al.190 have recently suggested that nucleic acids may be transported 
via an endocytotic mechanism and have provided data showing that GFP gene expression 
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was diminished by over 20% in B16-F10 cells when treated with 80 μM of dynasore, an 
endocytotic inhibitor. Interesting, Vaughan et al.179 have provided data supporting 
trafficking via microtubules in TC7 cells and A549 cells. Vaughan et al.179 showed that 
A549 cells treated immediately after electroporation with 10 μM of taxol, a microtubule 
network stabilizing agent, produced a 4.5 fold increase in luminescence 2 hours after 
transfection with luciferase DNA. Zaharoff et al.200 and Lukacs et al.103 provided evidence 
that suggested that DNA does not diffuse through the cell cytoplasm after microinjection and 
electroporation, but in fact must traffic via another mechanism such as endocytosis or via 
some form of convection.
Despite the many discrepancies over how electroporation works, a few general themes have 
been observed. There are distinct physical and biological considerations that must be 
tailored for each tissue to achieve maximum transfection efficiency. The size and type of the 
cell, nucleic acid concentration, and orientation of the cell are important factors to consider 
when adjusting pulse duration, pulse shape (e.g., square wave vs. exponential decay), and 
electric field strength, to achieve maximum transfection efficiency. Jordan et al.79 directly 
addressed how to tailor physical parameters of electroporators to achieve maximum 
transfection efficiency in a variety of cell lines that are difficult to transfect. For example, 
morphological characteristics between human umbilical vein endothelial cells (HUVECs) 
and neuroblastomas differ dramatically.42, 79, 107 Thus, the voltage, pulse shape, pulse 
duration, nucleic acid quantity, and cell density must be experimentally determined for each 
cell type to achieve maximum transfection efficiency, cell viability, and gene 
expression.74, 104, 162 Mehier-Humbert et al.108 suggested that long pulses (20–60 ms) 
combined with modest field strengths (100 – 200 V/cm) produce larger pores in cell 
membranes that remain open for longer durations. Tailoring electroporation parameters is 
especially important for improving the stability of gene expression in primary cells such as 
HUVECs, neurons, and Jurkat cells, which are not as robust to electroporation procedures as 
skeletal muscle fibers, which are very robust to electroporation.102, 115, 121, 153, 173, 198
Another important component to consider in electroporation is the electrodes that are used to 
generate the electric field. Normally, electrodes are directly applied to the tissue in vivo or a 
cell culture in vitro. A variety of electrodes have been developed for different applications 
commercially, and several investigators have built custom electrodes for specific 
applications. The strength, orientation, shape, and homogeneity of the electric field are 
directly dependent on the geometry and spacing of the individual electrodes.108 
Furthermore, the material used to coat the surface of the electrode that interacts directly with 
the tissue can affect the transfection efficiency. Stainless steel is commonly chosen to 
minimize ion stripping during electroporation, which can change the pH of the suspension 
buffer of cells and increase cell toxicity.7 A variety of different electrodes have been 
developed for different applications, which include plate electrodes, needle electrodes, and 
catheter electrodes.68 Plate electrodes are commonly used for electroporation of surface 
tissues and for in vitro electroporation of cell suspensions in cuvettes. Needle electrodes are 
used to electroporate deep tissues in vivo, and catheter electrodes have been developed to 
electroporate blood vessels.108 Figure 4 illustrates how plate electrodes and needle 
electrodes can be used to transfect cells in vitro and in vivo, respectively. Plate electrodes are 
able to generate more uniform (defined and homogenous) electric fields, but usually require 
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stronger voltages for electroporation. Needle electrodes allow for more flexibility and 
customizability in setting up electric fields, but at the expense of less homogenous electric 
fields.7, 68
Many viral and chemical vectors have limited efficiency in non-dividing cells, but 
electroporation has successfully transfected both dividing and non-dividing cells.3, 198 For 
tissue engineering applications, transfection of non-dividing cells is a highly desirable 
attribute as several primary cells in cartilage, bone, and neurons have rates of division that 
are too slow for passive gene delivery.90, 133, 153, 156 Furthermore, electroporation has been 
shown to transfect progenitor cells and stem cells, which is another highly desirable attribute 
for tissue engineering, as many groups focus on utilizing various stem cell sources for 
differentiation and tissue regeneration.6, 46
Despite the advantages of electroporation, there are some major limitations restricting its 
use. First, several physical and biological parameters must be carefully tailored for each 
tissue to achieve maximum transfection efficiency, which can be tedious. Second, 
electroporation may be able to efficiently transport nucleic acids into cells, but the benefit 
usually comes at a cost of low cell viability. Low cell viability is a major disadvantage of 
electroporation. Low cell viability may be a result of some cells undergoing irreversible 
electroporation or cells may die because of an increased cytotoxicity occurring from 
changing pH, resulting from the use of electrodes with poor biocompatibility. Furthermore, 
when electroporating tissues directly in vivo, there is the risk of producing inflammation, as 
not all cells will survive the procedure, and there may be a deposition of metal ions into the 
tissues from the electrodes. Another disadvantage of electroporation is that the up-front cost 
can be expensive, depending on the model of pulse generator and the associated electrodes. 
Furthermore, if in vivo studies are being conducted, a specially trained physician or 
technician must be present to properly place the electrodes on the subject to prevent injury 
and ensure proper alignment and generation of the electric field.
In summary, electroporation has great potential in tissue engineering and for gene vaccine 
applications, as electroporation is able to successfully transfect a variety of cells in vitro and 
in vivo, including dividing and non-dividing cells. However, electroporation can be an 
invasive procedure depending on the target tissue, and electroporation is notorious for 
producing low cell viabilities. However, unlike other transfection techniques, electroporation 
can transfect a large number of cells. Furthermore, the electroporative technology is rapidly 
evolving, and new systems are being developed each year to address the issues noted above. 
Nucleofection™ by Amaxa is a leading electroporative system that will be further discussed 
below for tissue engineering applications. The Nucleofection™ system attempts to mitigate 
the issue of low cell viability while increasing transfection efficiency.
NUCLEOFECTION™
Nucleofection™ has had incredible wide-reaching success in tissue engineering and cancer 
studies, compared against other physical non-viral gene delivery methods, and is therefore 
highlighted with special emphasis in this review. Nucleofection™ is a patented commercial 
electroporation system created by Amaxa, and owned by Lonza. Nucleofection™ is an 
electroporator that uses a sterile disposable cuvette to facilitate electroporation, Amaxa has 
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developed a variety of cell specific buffers that are proprietary, and are designed to enable 
maximum transfection while reducing cell death. In addition to the cell specific buffers, the 
Nucleofector™ comes pre-programmed with an assortment of programs specific to different 
cell lines that vary voltage, frequency, and pulse duration. However, the voltage, frequency, 
and pulse duration for each cell type are not revealed to the user, although Amaxa does 
provide suggested protocols for the user. The Nucleofection™ system has gained great 
popularity among many researchers as the Nucleofector™ is able to transfect many difficult-
to-transfect cells, including several progenitor cells and stem cells. For example, Aslan et 
al.8 transfected human bone marrow-derived stem cells (hBMSCs) at a density of 5 × 105 
with 5 μg of plasmid DNA expressing human bone morphogenetic protein 2 (hBMP2) and 
human bone morphogenetic protein 9 (hBMP9) via Nucleofection™ and achieved a 
transfection efficiency of 68 ± 41%. Furthermore, hBMSCs transfected with hBMP2 
produced an 8 to 16-fold increase in recombinant BMP2 secretion 24 hours after transfection 
via quantification through an enzyme-linked immunosorbent assay (ELISA). Aslan and 
colleagues confirmed that the Nucleofected™ cells were able to form new bone tissue both 
in vitro and in vivo through RT-qPCR, micro computed tomography (μCT), and 
immunohistochemistry. In an additional example, Bowles et al.17 used a Nucleofector-96-
Shuttle™ to transfect naïve dendritic cells at a density of 5 × 105 cells per 100 μL with 0.25 
μg of retinoic acid-inducing gene 1 (RIG-I) small interfering RNA (siRNA) to knockdown 
the RIG-I viral recognition receptor. Bowles et al. determined through RT-qPCR and western 
blotting that Nucleofection™ enabled a 75% knockdown of the detection of RIG-I. In a third 
experiment, Gonzalez et al.59 successfully generated induced pluripotent stem cells (iPSCs) 
by Nucleofecting™ mouse embryonic fibroblasts with a polycistronic construct containing 
octamer-binding transcription factor 4 (Oct4), (sex determining region Y)-box 2 (Sox2), 
krueppel-like factor 4 (Klf4), and v-myc myelocytomatosis viral oncogene homolog (avian) 
(c-Myc). The identities of the iPSCs were confirmed via RT-qPCR, Southern blotting, and 
western blotting. Furthermore, iPSCs were differentiated in vitro toward neuronal lineages, 
cardiomyocyte lineages, or endoderm lineages. In addition to these studies, several more 
have summarized the ability of Nucleofection™ to successfully transfect progenitor cells, 
stem cells, and connective tissues (Table 1), and the Nucleofection™ technique has been 
successfully used for gene knockdown studies in a variety of cells (Table 2). However, as 
displayed in the tables, not all cell types tolerate Nucleofection™ well. Some cells types lack 
desirable cell viabilities. Thus, the cell types lacking high cell viabilities may require more 
customization of buffer solution, electrical parameters, or a combination of both to increase 
viability.
Thus, in summary, Nucleofection™ is an effective transfection method for difficult-to-
transfect cells, and Nucleofection™ can facilitate high transfection in a variety of cell types, 
which makes Nucleofection™ an attractive technique for in vitro and ex vivo tissue 
engineering applications.
SONOPORATION
Similar to electroporation methods, high-intensity ultrasound has demonstrated the ability to 
induce pore formation in cell membranes, and allow for movement of plasmid DNA into cell 
cytosol.48 This method is commonly referred to as “sonoporation,” and in contrast to 
Mellott et al. Page 11













electroporation methods, induces pore formation through physical movement of fluid rather 
than using an electric field. Ultrasound is used in the clinic for diagnostic imaging, kidney 
stone treatment, pain relief, and ablation of cancer tissues.80, 127, 175 High-intensity focused 
ultrasound (HIFU) produces localized shear forces in extracellular fluids that facilitate 
cavitation, or the controlled collapse of air bubbles present in the surrounding fluid, and 
induce pore formation in cell membranes, increasing the permeability of cells to plasmid 
DNA and drugs (Fig. 5).128, 143, 189 Cavitation can be enhanced with the use of ultrasound 
contrast agents, such as Optison™, and drugs and nucleic acids can be complexed with 
contrast agents for systemic delivery.199 Zhou et al.207 have examined the effects of pore 
formation in Xenopus oocytes, and have found that the resealing of pores is affected by 
extracellular calcium concentration. Zhou et al.207 observed that pores induced by 
sonoporation in Xenopus oocytes resealed in 6 to 26 seconds in the presence of 1.8 mM 
Ca2+, whereas in contrast pores resealed between 58 to 170 seconds after sonoporation in 
the presence of 0.54 mM Ca2+. Sonoporation has gained popularity in clinical settings 
because it is non-invasive, and already used in the clinic to enhanced transdermal absorption 
of drugs. Furthermore, Newman et al.125 have reviewed the use of sonoporation on a variety 
of cell types and tissues, and noted that sonoporation seems to be a less destructive method 
for delivery of plasmid DNA than electroporation. Currently, sonoporation is primarily used 
to enhance drug delivery and gene delivery to diseased tissues in vivo rather than for tissue 
engineering applications. Interestingly, Liang et al.98 have noted that sonoporation has 
exhibited enhanced transfection efficiency in tissues such as the heart, blood vessels, lung, 
kidney, brain, muscles, and the tumors when physical parameters of sonoporation are 
optimized.
Sonoporation is limited by relatively poor control of the energy localization. While 
sonoporation can induce cavitation in tissues, there currently is no way to control the 
uniformity of the cavitation or the entry of DNA. Complexation of DNA and contrast agents 
have greatly improved targeting; however, each target tissue needs to be carefully evaluated 
to ensure that cavitation induces pore formation in target cells.108 Thus, sonoporation cannot 
be as precisely controlled as in electroporation, where cells are placed between electrodes. 
Furthermore, sonoporation seems to be more effective in vivo for tissues that are in direct 
contact with blood vessels.
In summary, sonoporation is effective for transfecting cells in vivo as it is non-invasive, and 
already used in the clinical setting. However, sonoporation exhibits lower transfection 
efficiencies because cavitation cannot be precisely controlled within the tissue. Improving 
the uniformity of cavitation for membrane pore formation and improving the accuracy of 
cell contrast could make sonoporation highly effective for tissue engineering.
LASER IRRADIATION
Laser irradiation is an alternative strategy under investigation for gene delivery applications. 
Investigators have used neodymium-doped yttrium aluminum garnet (Nd:YAG), holmium-
YAG, titanium sapphire, and argon powered lasers to perforate cells to enable the entry of 
DNA by varying the pulse frequency of the laser.130, 152, 172, 202 Typically, a laser is focused 
through an objective onto a localized area of an individual cell in culture and increases the 
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permeability of the cell to exogenous DNA in the culture medium. Interestingly, cells seem 
to not undergo any lethal injury when perforated by a laser, and they are able to repair the 
“holes” made by perforations in less than a second.93, 130 Furthermore, a laser can be used 
indirectly to induce stress waves in the medium to perforate cells temporarily to enable the 
entry of DNA. Yao et al.197 provided a comprehensive review of the different methods to use 
a laser to facilitate gene delivery in cell culture. Ogura et al.129 demonstrated the precision 
and efficiency of using laser irradiation by injecting Sprague-Dawley rats with plasmid DNA 
coding for enhanced green fluorescent protein (EGFP) and luciferase. Ogura and colleagues 
injected Sprague-Dawley rats with 50 μg of plasmid DNA and irradiated the injection area 
with six pulses of 1.9 J/cm2 fluence laser, which produced a luminescent expression of 105 
relative light units (RLUs) per milligram of protein for up to 5 days. EGFP expression was 
confined to the exact area of skin irradiated with the laser 24 hours after transfection. In 
another report, Shirahata et al.167 successfully delivered EGFP to HuH-7 and NIH/3T3 cells 
in culture by using a pulsed 355 nm Nd:YAG laser to perforate cells, while a 1015 nm 
continuous-wave Nd:YAG laser was used to trap individual cells. Figure 6 provides an 
illustration of a cell undergoing perforation by a pulsed laser while being immobilized by a 
continuous laser. Shirahata and colleagues achieved a transfection efficiency of 10% in 
NIH/3T3 cells when DNA was delivered at a concentration of 10 μg/mL.
Laser irradiation has great potential for tissue engineering as it can be used to target precise 
cells in tissue or in culture. Laser irradiation is less invasive than microinjection or 
electroporation as no needle is required and individual cells can be targeted. The brief 
perforation of the cell by a pulsed laser seems not to cause cell death. Furthermore, optical 
fibers can deliver laser light that can be controlled by computers, and may eventually 
provide convenient access to tissues inside the body that were previously inaccessible.197
However, despite the advantages of laser irradiation, some key limitations exist. While 
precise and efficient, laser irradiation is still a young technology, and more studies are 
needed to determine how robust the procedure is on different cell types. Laser irradiation is 
highly efficient at targeting individual cells, but it is not efficient at targeting large 
populations of cells efficiently. In addition, optical lasers can be very large and costly. 
Furthermore, specialized training is required to operate an optical laser properly.
In summary, laser irradiation has great potential for gene therapy and tissue engineering 
applications as optical lasers can be used to precisely target individual cells in culture or in 
tissue. However, laser irradiation is still a young technology that needs further investigation, 
and is costly. Nevertheless, as laser irradiations strategies improve and the technology is 
further investigated, optical lasers may allow investigators to target tissues for gene therapy 
and tissue engineering in ways that were previously not possible.
EMERGING TECHNIQUES IN GENE DELIVERY
In contrast to the techniques described above, there are additional techniques under 
development that may prove advantageous for specific gene delivery and tissue engineering 
applications. Here we briefly describe the techniques of electric field-induced molecular 
vibration gene delivery, a novel technique introduced by Tuan and colleagues in 2004 170, 
and magnetofection, a technique used as a tool to enhance gene delivery strategies.
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Tuan et al.170 developed a unique gene delivery method known as electric field-induced 
molecular vibrations as an alternative to electroporation to facilitate high transfection 
efficiencies in mesenchymal progenitor cells and a variety of cell lines. Tuan and colleagues 
created a unique apparatus where cells and DNA are suspended in a glass dish that 
undergoes vigorous vibration induced by two electrodes.170 The electrodes do not directly 
contact the cells, and no current is applied across the cells; however, the vigorous shaking 
enables exogenous molecules to penetrate the cell membrane and reach the cytoplasm. 
According to Tuan et al.170 electric field-induced vibration transfection is economical and 
efficient because it requires no additional reagents and exhibits high transfection efficiency 
with low cell mortality. Furthermore, Tuan et al.170 noted that electric field-induced 
molecular vibration transfection does not interfere with cell proliferation, and provides 
stable gene expression. Limited literature is available on this technique; however, if these 
claims and data can be verified then electric field-induced molecular vibration transfection 
could be a suitable transfection technique for ex vivo and in vitro tissue engineering 
applications. Tuan et al.170 report several data values regarding transfection efficiency and 
cell viability for multiple cell lines using different parameters for the electric field-induced 
vibration apparatus. Most notably, Tuan and colleagues reported a maximum transfection 
efficiency of 9.4 ± 9.3% and a maximum cell viability of 57 ± 40% for human mesenchymal 
stem cells when a frequency of 120 Hz was used in combination with a 12 V setting and a 
wave ratio of 300 for the parameters of the electric field-induced molecular vibration 
apparatus.
Magnetofection is a technique that exploits the energy of a magnetic field to enhance the 
delivery efficiency of DNA, siRNA, or shRNA via viral or non-viral vectors.35, 43, 49, 160 
Paramagnetic particles typically made of iron oxide are coated with viral particles, 
liposomes, or cationic polymers and combined with nucleic acids.73, 75, 160 Several in vitro 
studies have placed a magnetic plate underneath a cell culture vessel once the magnetic 
particles and gene delivery vector have been combined with the target tissue of cells to 
preferentially direct or “pull” the magnetic particles into cells or tissue explants.196 
Magnetofection does not necessarily improve the transfection efficiency of gene delivery 
methods; instead, magnetofection increases the speed at which nucleic acids traffic into the 
cell and nucleus while enabling smaller doses of nucleic acids to be used.140 Plank et 
al.139, 141 have published insightful reviews on how magnetofection works and the potential 
benefits of magnetofection on in vitro gene delivery applications. In addition, 
magnetofection has been used to enhance gene delivery to primary cells such as neurons and 
endothelial cells in vitro, and has been applied to enhance gene delivery to the 
gastrointestinal tract and blood vessels in vivo.19, 91, 137, 155, 160, 163 Sapet et al.155 were able 
to achieve a transfection efficiency of approximately 15%, 48 hours after transfection in 
primary neuronal stem cells from P1 mice using a magnetofection reagent, NeuroMag. This 
finding may be considered impressive because neuronal cells are known to be incredibly 
difficult to transfect. As new technologies develop, magnetofection could prove quite 
valuable for enhancing tissue engineering applications.
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APPLICATIONS OF GENE DELIVERY TO TISSUE ENGINEERING
The goal behind integrating gene therapy and tissue engineering together is to manipulate 
the behavior of cells so that cells can be used to produce proteins and associate into tissues 
that are capable of replacing, restoring, regenerating, or enhancing the function of tissue 
defects within the human body. The marriage of these two fields is not a new idea. In fact, 
there are a multitude of examples where gene therapy and tissue engineering have been 
integrated for enhancing differentiation strategies. Most of the studies have focused on ex 
vivo or in vitro approaches for integrating gene therapy into tissue engineering. Multiple 
groups have used a variety of synthetic polymers (PEI), biodegradable polymers (PLL-PA, 
PBAE, PLGA), and biological polymers (chitin, fibrin, collagen) to either encapsulate or 
anchor nucleic acids to the scaffolding material on which cells are seeded for nucleic acid 
uptake.16, 29, 53, 54, 60, 62–64, 76, 97, 99, 126, 138, 158, 194 Several of the studies have shown 
sustained gene delivery for periods up to two to three weeks, but the overall transfection 
efficiency has varied. Polymers provide flexibility in designing scaffolds to accommodate 
stem cells for differentiation, and the incorporation of nucleic acids to direct differentiation 
is a natural progression. However, no one polymer has emerged as a reliable vector for 
primary cells, progenitor cells, and stem cells. Nor should any one polymer be expected to 
successfully transfer nucleic acids to all cell types. While it seems several investigators 
within the field of tissue engineering have placed an emphasis on trying to deliver nucleic 
acids via polymers, others have focused on physical methods. Cesnulevicius et al.22 
transfected mesencephalic neuronal progenitor cells from Sprague-Dawley rats with 
fibroblast growth factor 2 (FGF-2) linked to enhanced green fluorescent protein (EGFP) via 
Nucleofection™ and found that the transfected cells tested positive for nestin, an important 
protein for neuron growth. Furthermore, the cells were able to survive transplantation into 
lesioned rat brains, demonstrating a potential for developing a new primary transplantation 
method for neuronal tissues. The significance of the work by Cesnulevicius et al.22 is that 
they achieved a transfection efficiency of 47% in neuronal progenitor cells, which is high for 
a non-viral method, especially because neuronal tissues are notoriously difficult to transfect. 
Additionally, Cesnulevicius et al.22 detected FGF-2 expression up to 11 days after 
transfection. This study shows promise for using physical non-viral gene delivery vectors, in 
this case Nucleofection™.
In a different experiment, Duffy et al.41 5 × 105 transfected human mesenchymal stem cells 
(hMSCs) with 2 μg of plasmid DNA expressing Ephrin-B2 via Nucleofection™ and achieved 
a transfection efficiency of approximately 45%. hMSCs have been known not to transfect 
easily. Furthermore, in this study, the hMSCs expressed Ephrin-B2 and took on early 
endothelial phenotype and are thought to have contributed to the increased detection of 
VEGF in cell culture, which could potentially promote angiogenesis in ischemic tissues. 
Like the work published by Duffy et al.41 and Cesnulevicius et al.,22 several investigators are 
exploring strategies to isolate cells and transform them outside of the body either by 
chemical or physical methods for therapeutic purposes.25, 37, 72 However, while there has 
been a focus on using ex vivo and in vitro strategies for integrating gene therapy and tissue 
engineering, much of the field of gene therapy has focused on using in vivo methods to for 
therapeutic purposes. Thus, perhaps it might be worth reversing the idea of integrating gene 
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therapy into tissue engineering, and instead look at how to integrate tissue engineering 
strategies into gene therapy. To better understand how to apply tissue engineering strategies 
to gene therapy, it would be best to focus on the limitations and challenges that restrict gene 
delivery.
UNDERSTANDING CHALLENGES THAT LIMIT NON-VIRAL GENE DELIVERY
Every single vector must first cross the plasma membrane. However, before a delivery 
vehicle reaches the cell membrane, there are obstacles to overcome. For example, most cells 
in a connective tissue are located within the labyrinth of the extracellular matrix (ECM). 
Some investigators have suggested that the collagen in the ECM could be hindering the 
diffusion of large nucleic acids and other macromolecules, preventing them from reaching 
the target cell surface.122, 142 Thus, one approach to overcome this limitation is to disrupt the 
ECM. Disrupting the ECM in vivo could pose difficulties for the subject; however, if the 
target tissue is excised, the ECM could be disrupted with trypsin to expose cell membranes. 
An additional consideration is that electrophoresis may be able to help move nucleic acids 
through the ECM, but this process, depending on the tissue, may not be able to bring the 
nucleic acids close enough to the cell membrane for interaction.71 Thus, the ECM may be an 
additional barrier to consider when designing delivery vectors.
Beyond the ECM, the cell membrane remains a significant barrier for all delivery vectors. 
Many chemical vectors attempt to associate the nucleic acid delivery vehicle with the cell 
membrane through electrostatic interactions, ligand mediated receptor binding, and through 
adsorption. Several studies suggest that association with the cell membrane is required for 
entry into the cytoplasmic compartment of the cell.44, 47, 55, 65, 145 However, microinjection 
and ballistic gene delivery bypass the cell membrane by directly transporting nucleic acids 
into the cell cytoplasm or the nucleus. Electroporation, sonoporation, and laser irradiation 
disrupt the cell membrane to facilitate infiltration of nucleic acids. However, microinjection, 
ballistic gene delivery, electroporation, sonoporation, and laser irradiation display one 
common weakness. All methods rupture the cell membrane in some fashion, and if the cell 
is unable to mend the membrane, then the cell dies. Thus, taking a closer look at the function 
of the cell membrane may provide questions and answers to finding ways to better overcome 
this important barrier and maximize cell viability.
What is the plasma membrane? Simply, the plasma membrane is a barrier to separate two 
hydrophilic compartments, namely, the intracellular space and the extracellular space. The 
plasma membrane is composed of a phospholipid bilayer with proteins permeating both the 
intracellular and extracellular sides of the plasma membrane.5, 20 Furthermore, the 
composition of lipids and proteins can vary among cell types, and the plasma membrane is 
not a rigid structure, meaning that lipids and proteins are not static, but rather moving 
targets. The composition of the cell membrane can have an influence on the physical and 
mechanical functions of the cell membrane. For example, cells that are a part of tissues that 
provide structure and support (e.g., bone) may be more inflexible and rigid, containing fewer 
unsaturated lipids to maintain a less fluid structure, and hence lower membrane permeability, 
whereas secretory cells may contain more unsaturated lipids and fewer proteins to maintain 
a more fluid membrane composition that is more permeable.5 Furthermore, depending on 
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the target cell and the condition of the tissue (i.e., adherent cells or cells in suspension), 
access to the plasma membrane may be restricted. Thus, an appropriate questions is “does 
exposure to cell surface affect localization of nucleic acids on the surface?” Adler et al.2 
endeavored to address this very subject by exploring the effect of cell surface topography on 
transfection efficiency. Adler plated fibroblasts onto micropitted surfaces at varying densities 
and found a 25% increase in transfection efficiency when using Lipofectamine 2000™ to 
deliver GFP for cells plated on densely pitted surfaces as opposed to smooth surfaces. This 
increase could have been attributed to a variety of factors. The cells did spread across the 
pitted surfaces, but not on the smooth surfaces. So why did transfection efficiency increase? 
Were delivery vehicles able to associate with the cell membrane because the membrane had 
an increased surface area? Did the composition of the membrane change because of the cell 
spreading across the pitted surface? Adler suggested that a consequence of the cell spreading 
was a loss of integrin mediated cell adhesion, which resulted in the internalization of 
caveolae, and could have been responsible for a down regulation of particle uptake through 
competitive mechanisms. The spreading of cells on pitted surfaces did not lead to an 
increase in cell proliferation. Thus, the rate of cellular mitosis did not increase, which means 
passive diffusion of DNA into the cell nucleus was not responsible for the increase in gene 
expression. Adler’s study was exciting because it drew attention to the consideration of 
surface topography, and presented questions about how nucleic acids associate with the cell 
membrane and how the cell membrane might be altered to accommodate molecules. Perhaps 
the permeability of a cell membrane can be manipulated mechanically to alter firmness or 
fluidity for delivery vectors. An exciting and recommended next step would be to see how 
other non-viral vectors perform when a cell spreads. For example, combining cell spreading 
with an electroporative technique would be an exciting study to investigate how cell 
spreading affects the ability of the cell to permeabilize and mend under an electric field. 
Another question to ask is whether different cell types produce the same results when 
cultured on pitted surfaces.
Chalut et al.23 presented an additional insight regarding the influence of changing 
mesenchymal stem cell (MSC) membrane topography and how deforming the MSC changes 
the structure of its nucleus. As the nucleus is connected via the cytoskeleton to the cell 
membrane, mechanical forces on the cell membrane act via the cytoskeleton on the nucleus. 
They offered evidence that is consistent with findings in the literature that the nucleus 
changed shape in response to the deformation of the cell.23, 96, 168 If the nucleus can alter its 
shape in response to mechanical forces exerted on the cytoskeleton, then how does gene 
expression change? Does the elongation of the nucleus in response to mechanical forces 
acting on the cell increase transfection efficiency by shortening the distance between the cell 
membrane and nucleus? These questions need further investigation.
Despite the interest in the membrane topography and deformation of the nucleus as they 
relate to gene expression, there is an additional parameter to consider. Chemical vectors tend 
to use an endocytotic route of delivery once the nucleic acids have entered the cell, while 
physical vectors attempt to deliver nucleic acids directly to the cytoplasm or nucleus. 
However, chemical methods seem to have higher cell viabilities, but low transfection rates in 
primary cells, progenitor cells, and stem cells, whereas the opposite is true for physical 
methods. Thus, the questions arises, “how do nucleic acids traffic through the cytoplasm?” 
Mellott et al. Page 17













Nucleic acids must escape endosomes to avoid degradation by lysosome enzymes, but then 
how do the nucleic acids reach the interior of the nucleus? Dividing cells provide an 
opportunity on a regular interval as the nuclear envelope deconstructs during mitosis, and 
reforms at the conclusion of mitosis. In non-dividing cells, the nucleic acids must enter 
through a nuclear pore. Thus, how do the nucleic acids reach the nuclear pore? Zaharoff et 
al.200 suggested the nucleic acids do not diffuse through the cytoplasm, but move by some 
other mechanism such as convection. Lukacs et al.103 presented work that was consistent 
with Zaharoff et al.200 in that DNA did not seem to diffuse through the cytoplasm. Vaughan 
et al.179 provided evidence that suggested that nucleic acids may traffic via microtubules. 
Unfortunately, there is still very little that is known about how nucleic acids traffic through 
the cytoplasm. Elucidating how nucleic acids traffic through the cytoplasm will be crucial to 
improving future vectors.
What is really needed now are studies that focus on applying tissue engineering approaches 
to gene therapy, and elucidating the mechanism by which cells can be manipulated to better 
take up DNA, siRNA, shRNA, miRNA, and antisense oligonucleotides to affect gene 
expression. Adler et al.2 and Chalut et al.23 presented interesting data on manipulating the 
physical parameters and behaviors of cells using chemical delivery methods. The next step 
forward should be to apply the same cell manipulations to a physical delivery method such 
as ballistic gene delivery or electroporation to determine whether the physical manipulations 
of the cell can enhance physical gene delivery methods for tissue engineering applications. 
Increasing the quantitative assessment of studies that combine both gene delivery and tissue 
engineering are key to enhancing both the fields. Furthermore, approaching gene therapy 
from a tissue engineering perspective might be a fresh way to reveal more details about how 
cells take up and express exogenous nucleic acids.
FUTURE DIRECTIONS AND OPPORTUNITIES
Improving physical non-viral gene delivery methods for tissue engineering applications 
requires an examination of the fundamental mechanisms utilized by each physical non-viral 
gene delivery method as well as the reason different cell types are more or less responsive to 
each gene delivery method. Elucidating the basic mechanisms by which physical non-viral 
gene delivery methods work and understanding why different cell types are responsive to 
different gene delivery methods will allow investigators to exploit the positive attributes of 
gene delivery methods and different cell types to enhance tissue engineering applications.
Microinjection is perhaps the most efficient and direct method for delivering nucleic acids to 
cells; however, the major weaknesses associated with microinjection are the restricted access 
to tissues, and the inability to transfect large numbers of cells. Likewise, ballistic gene 
delivery lacks access to tissues and is restricted by the quantity of nucleic acids that can be 
delivered. However, both of these methods have significant potential if the weaknesses 
previously stated can be overcome, as both methods can directly control the amount of 
nucleic acids directly delivered to individual cells.
In addition, electroporation, sonoporation, and laser irradiation seek to transiently disrupt the 
cell membrane to increase permeability of nucleic acids to the cells. Sonoporation is 
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attractive because it is already used in a clinical setting, but the tissues that are being 
targeted need to be extensively evaluated to produce maximum efficiency. Electroporation 
suffers the same weakness as sonoporation, yet electroporation has more flexibility for 
targeting cells, as the electric field can be controlled via a pulse generator and electrodes can 
be designed specifically for individual applications. However, electroporation still suffers 
from low cell viability. Laser irradiation can precisely target individual cells; however, laser 
irradiation is not efficient for targeting thousands of cells in different layers of tissues. In 
contrast, several non-viral chemical vectors exhibit high cell viabilities, but limited 
transfection efficiencies. Thus, it is necessary to look at which physical features enable the 
high cell viability of most non-viral chemical transfection vectors and which physical 
features enable moderate to high transfection in non-viral physical vectors. Perhaps it is best 
to consider these questions from the point of view of the cell and the environment of the cell 
to gain a better understanding of what affects cell viability and limits transfection.
If the cell can be physically manipulated, how else can non-viral vectors be improved? Is it 
possible to make cells more susceptible to electroporation or sonoporation by adjusting the 
osmolarity of the extracellular fluid? If the extracellular fluid is made to be hypotonic to the 
intracellular fluid of the cell to induce swelling of the cell, will the swelling produce similar 
responses in the cell membrane as cell spreading? These questions are important to consider 
when designing new vectors. Furthermore, can delivery vectors be combined to achieve 
higher transfection efficiencies? Is there a way to design a combinational polymer scaffold 
to where one polymer acts as an electrode and another polymer acts as an anchor for nucleic 
acids and an attachment platform for cells seeded into the scaffold to permit increased 
transfection efficiency?
Increasing the abilities of non-viral vectors to manipulate gene expression and mitigate cell 
death depend on finding ways to improve the uptake of nucleic acids into cells and 
minimizing the trauma to the cell membrane from points of entry. The physical methods 
described in this review are capable of overcoming the limitation of the cell membrane entry 
by directly acting on the cell membrane and forcing nucleic acids into the cytoplasm or even 
the nucleus. However, the method of membrane disruption can directly influence the cell’s 
ability to mend the membrane. The diameter of the “holes” created in the cell membrane and 
the duration for which these “holes” remain open seem to directly correlate with the cell’s 
ability to survive. As suggested by Mehier-Humbert et al.,108 larger pores that remain open 
for increased durations increase the uptake of nucleic acids; however, larger pores permit the 
exchange of additional agents that normally cannot cross the cell membrane increasing the 
risk that homeostatic concentration gradients will be disrupted leading to cell death. Thus, a 
balance needs to be struck between facilitating the entry of nucleic acids without 
compromising the homeostatic concentrations of ions such as Na+ and K+ inside and 
outside of the cell.
As investigations continue into how cell membranes and gene expression can be 
manipulated from a chemical and mechanical perspective, new mechanisms of how the cell 
membrane reseals and how nucleic acids are trafficked within the cytoplasm in different cell 
types are bound to be proposed in the literature. Elucidating these fundamental mechanisms 
will contribute to developing new delivery strategies that enhance the delivery of nucleic 
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acids with minimal risks to compromising the cell membrane. Perhaps even combinational 
approaches may yield beneficial consequences for gene transfer into target tissues. Tissue 
engineering currently focuses on manipulating cellular behavior externally by applying 
mechanical stimuli and different biomaterials to simulate native environments to aid in the 
differentiation of progenitor cells and stem cells. Perhaps considering the external 
environment as part of the nucleic acid delivery system is the key to changing the behavior 
of the cell to better accommodate nucleic acid delivery and improve differentiation of cells 
into target tissues for regeneration and tissue engineering applications.
The improvements in physical gene delivery methods over the past three decades have been 
impressive and have greatly enabled increased gene expression in difficult-to-transfect cells; 
however, the fundamental challenges still remain. Non-viral physical methods still focus on 
deforming the cell membrane in some manner to increase transfection rates at the expense of 
cell viability. However, investigators are working to elucidate mechanisms of how nucleic 
acids can cross the cell membrane and traffic through the cytoplasm to the nucleus. These 
endeavors are expected to lead to the development of new vectors that can increase the gene 
expression in cells without compromising significant numbers of cells in vitro or in vivo. 
Furthermore, exploration of how cellular behavior can be manipulated externally to achieve 
a desired behavior is of interest in tissue engineering, which may be key in developing new 
strategies to better facilitate cell differentiation. Thus, it would seem that applying a tissue 
engineering approach to gene therapy rather than a gene therapy approach to tissue 
engineering may be a potential solution for providing a fruitful integration of these two 
fields together to expand approaches for cell differentiation and tissue formation in tissue 
engineering and regenerative medicine applications.
References
1. Adler AF, Leong KW. Emerging links between surface nanotechnology and endocytosis: impact on 
nonviral gene delivery. Nano Today. 2010; 5:553–569. [PubMed: 21383869] 
2. Adler AF, Speidel AT, Christoforou N, Kolind K, Foss M, Leong KW. High-throughput screening of 
microscale pitted substrate topographies for enhanced nonviral transfection efficiency in primary 
human fibroblasts. Biomaterials. 2011; 32:3611–9. [PubMed: 21334062] 
3. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol. 1998; 
16:867–70. [PubMed: 9743122] 
4. Akinc A, Thomas M, Klibanov AM, Langer R. Exploring polyethylenimine-mediated DNA 
transfection and the proton sponge hypothesis. J Gene Med. 2005; 7:657–63. [PubMed: 15543529] 
5. Alberts, B.; Bray, D.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walter, P.; Campbell, A. 
Essential cell biology. Garland Science; New York: 2004. 
6. Aluigi M, Fogli M, Curti A, Isidori A, Gruppioni E, Chiodoni C, Colombo M, Versura P, D’Errico 
Grigioni A, Ferri E. Nucleofection Is an Efficient Nonviral Transfection Technique for Human Bone 
Marrow-Derived Mesenchymal Stem Cells. Stem Cells. 2006; 24:454–461. [PubMed: 16099993] 
7. Andre FM, Mir LM. Nucleic acids electrotransfer in vivo: mechanisms and practical aspects. Curr 
Gene Ther. 2010; 10:267–80. [PubMed: 20557285] 
8. Aslan H, Zilberman Y, Arbeli V, Sheyn D, Matan Y, Liebergall M, Li J, Helm G, Gazit D, Gazit Z. 
Nucleofection-based ex vivo nonviral gene delivery to human stem cells as a platform for tissue 
regeneration. Tissue Engineering. 2006; 12:877–889. [PubMed: 16674300] 
9. Baertschi AJ. Antisense oligonucleotide strategies in physiology. Mol Cell Endocrinol. 1994; 
101:R15–24. [PubMed: 9397970] 
Mellott et al. Page 20













10. Baksh D, Yao R, Tuan R. Comparison of proliferative and multilineage differentiation potential of 
human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells. 2007; 
25:1384–1392. [PubMed: 17332507] 
11. Baoum A, Dhillon N, Buch S, Berkland C. Cationic surface modification of PLG nanoparticles 
offers sustained gene delivery to pulmonary epithelial cells. J Pharm Sci. 2010; 99:2413–22. 
[PubMed: 19911425] 
12. Baoum A, Ovcharenko D, Berkland C. Calcium condensed cell penetrating peptide complexes 
offer highly efficient, low toxicity gene silencing. Int J Pharm. 2011
13. Baoum AA, Berkland C. Calcium condensation of DNA complexed with cell-penetrating peptides 
offers efficient, noncytotoxic gene delivery. J Pharm Sci. 2011; 100:1637–42. [PubMed: 
21374602] 
14. Bier M, Hammer SM, Canaday DJ, Lee RC. Kinetics of sealing for transient electropores in 
isolated mammalian skeletal muscle cells. Bioelectromagnetics. 1999; 20:194–201. [PubMed: 
10194562] 
15. Bittman KS, Panzer JA, Balice-Gordon RJ. Patterns of cell-cell coupling in embryonic spinal cord 
studied via ballistic delivery of gap-junction-permeable dyes. J Comp Neurol. 2004; 477:273–85. 
[PubMed: 15305364] 
16. Bolliet C, Bohn MC, Spector M. Non-viral delivery of the gene for glial cell line-derived 
neurotrophic factor to mesenchymal stem cells in vitro via a collagen scaffold. Tissue Eng Part C 
Methods. 2008; 14:207–19. [PubMed: 18721070] 
17. Bowles R, Patil S, Pincas H, Sealfon SC. Validation of efficient high-throughput plasmid and 
siRNA transfection of human monocyte-derived dendritic cells without cell maturation. J Immunol 
Methods. 2010; 363:21–8. [PubMed: 20875421] 
18. Bradburne C, Robertson K, Thach D. Assessment of methods and analysis of outcomes for 
comprehensive optimization of nucleofection. Genet Vaccines Ther. 2009; 7:6. [PubMed: 
19432988] 
19. Buerli T, Pellegrino C, Baer K, Lardi-Studler B, Chudotvorova I, Fritschy JM, Medina I, Fuhrer C. 
Efficient transfection of DNA or shRNA vectors into neurons using magnetofection. Nat Protoc. 
2007; 2:3090–101. [PubMed: 18079708] 
20. Campbell, N.; Mitchell, L.; Reece, J. Biology: concepts & connections. Benjamin Cummings; New 
York: 2003. 
21. Cemazar M, Golzio M, Sersa G, Rols MP, Teissie J. Electrically-assisted nucleic acids delivery to 
tissues in vivo: where do we stand? Curr Pharm Des. 2006; 12:3817–25. [PubMed: 17073680] 
22. Cesnulevicius K, Timmer M, Wesemann M, Thomas T, Barkhausen T, Grothe C. Nucleofection is 
the most efficient nonviral transfection method for neuronal stem cells derived from ventral 
mesencephali with no changes in cell composition or dopaminergic fate. Stem Cells. 2006; 
24:2776–91. [PubMed: 16902196] 
23. Chalut KJ, Kulangara K, Giacomelli MG, Wax A, Leong KW. Deformation of stem cell nuclei by 
nanotopographical cues. Soft Matter. 2010; 6:1675–1681. [PubMed: 21297875] 
24. Check E. Gene therapy put on hold as third child develops cancer. Nature. 2005; 433:561.
25. Chew SA, Kretlow JD, Spicer PP, Edwards AW, Baggett LS, Tabata Y, Kasper FK, Mikos AG. 
Delivery of plasmid DNA encoding bone morphogenetic protein-2 with a biodegradable branched 
polycationic polymer in a critical-size rat cranial defect model. Tissue Eng Part A. 2011; 17:751–
63. [PubMed: 20964581] 
26. Choi SO, Kim YC, Park JH, Hutcheson J, Gill HS, Yoon YK, Prausnitz MR, Allen MG. An 
electrically active microneedle array for electroporation. Biomed Microdevices. 2010; 12:263–73. 
[PubMed: 20012696] 
27. Cinkornpumin JK, Hong RL. RNAi mediated gene knockdown and transgenesis by microinjection 
in the necromenic Nematode Pristionchus pacificus. J Vis Exp. 2011:e3270. [PubMed: 22025167] 
28. Clackson T. Regulated gene expression systems. Gene Ther. 2000; 7:120–5. [PubMed: 10673717] 
29. Clements BA, Incani V, Kucharski C, Lavasanifar A, Ritchie B, Uludag H. A comparative 
evaluation of poly-L-lysine-palmitic acid and Lipofectamine 2000 for plasmid delivery to bone 
marrow stromal cells. Biomaterials. 2007; 28:4693–704. [PubMed: 17686514] 
Mellott et al. Page 21













30. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature. 2003; 422:37–44. 
[PubMed: 12621426] 
31. Cui M, Wan Y, Anderson DG, Shen FH, Leo BM, Laurencin CT, Balian G, Li X. Mouse growth 
and differentiation factor-5 protein and DNA therapy potentiates intervertebral disc cell 
aggregation and chondrogenic gene expression. Spine J. 2008; 8:287–95. [PubMed: 17974491] 
32. Dahlhoff M, Grzech M, Habermann FA, Wolf E, Schneider MR. A transgenic mouse line 
expressing cre recombinase in pancreatic beta-cells. Genesis. 2011
33. Dang JM, Leong KW. Natural polymers for gene delivery and tissue engineering. Adv Drug Deliv 
Rev. 2006; 58:487–99. [PubMed: 16762443] 
34. Daugimont L, Baron N, Vandermeulen G, Pavselj N, Miklavcic D, Jullien MC, Cabodevila G, Mir 
LM, Preat V. Hollow microneedle arrays for intradermal drug delivery and DNA electroporation. J 
Membr Biol. 2010; 236:117–25. [PubMed: 20652559] 
35. del Pino P, Munoz-Javier A, Vlaskou D, Rivera Gil P, Plank C, Parak WJ. Gene silencing mediated 
by magnetic lipospheres tagged with small interfering RNA. Nano Lett. 2010; 10:3914–21. 
[PubMed: 20836536] 
36. Denet AR, Vanbever R, Preat V. Skin electroporation for transdermal and topical delivery. Adv 
Drug Deliv Rev. 2004; 56:659–74. [PubMed: 15019751] 
37. Dichek DA, Neville RF, Zwiebel JA, Freeman SM, Leon MB, Anderson WF. Seeding of 
intravascular stents with genetically engineered endothelial cells. Circulation. 1989; 80:1347–53. 
[PubMed: 2509105] 
38. Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem. 2009; 78:857–902. 
[PubMed: 19317650] 
39. Donnelly RF, Raj Singh TR, Woolfson AD. Microneedle-based drug delivery systems: 
microfabrication, drug delivery, and safety. Drug Deliv. 2010; 17:187–207. [PubMed: 20297904] 
40. Dormer NH, Qiu Y, Lydick AM, Allen ND, Mohan N, Berkland CJ, Detamore MS. Osteogenic 
Differentiation of Human Bone Marrow Stromal Cells in Hydroxyapatite-Loaded Microsphere-
Based Scaffolds. Tissue Eng Part A. 2011
41. Duffy GP, D’Arcy S, Ahsan T, Nerem RM, O’Brien T, Barry F. Mesenchymal stem cells 
overexpressing ephrin-b2 rapidly adopt an early endothelial phenotype with simultaneous 
reduction of osteogenic potential. Tissue Eng Part A. 2010; 16:2755–68. [PubMed: 20491587] 
42. Ear T, Giguere P, Fleury A, Stankova J, Payet MD, Dupuis G. High efficiency transient transfection 
of genes in human umbilical vein endothelial cells by electroporation. J Immunol Methods. 2001; 
257:41–9. [PubMed: 11687237] 
43. Ensenauer R, Hartl D, Vockley J, Roscher AA, Fuchs U. Efficient and gentle siRNA delivery by 
magnetofection. Biotech Histochem. 2011; 86:226–31. [PubMed: 20297946] 
44. Faurie C, Rebersek M, Golzio M, Kanduser M, Escoffre JM, Pavlin M, Teissie J, Miklavcic D, 
Rols MP. Electro-mediated gene transfer and expression are controlled by the life-time of DNA/
membrane complex formation. J Gene Med. 2010; 12:117–25. [PubMed: 19941315] 
45. Favard C, Dean DS, Rols MP. Electrotransfer as a non viral method of gene delivery. Curr Gene 
Ther. 2007; 7:67–77. [PubMed: 17305529] 
46. Flanagan MB, Gimble JM, Yu G, Xia X, Bunnell B, Li S. Competitive DNA transfection 
formulation via electroporation for human adipose stem cells and mesenchymal stem cells. Biol 
Proced Online. 2012; 14:7. [PubMed: 22512891] 
47. Frantescu A, Kakorin S, Toensing K, Neumann E. Adsorption of DNA and electric fields decrease 
the rigidity of lipid vesicle membranes. Phys Chem Chem Phys. 2005; 7:4126–31. [PubMed: 
16474877] 
48. Frenkel V, Li KC. Potential role of pulsed-high intensity focused ultrasound in gene therapy. Future 
Oncol. 2006; 2:111–9. [PubMed: 16556078] 
49. Gersting SW, Schillinger U, Lausier J, Nicklaus P, Rudolph C, Plank C, Reinhardt D, Rosenecker 
J. Gene delivery to respiratory epithelial cells by magnetofection. J Gene Med. 2004; 6:913–22. 
[PubMed: 15293350] 
50. Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Control Release. 2007; 
117:227–37. [PubMed: 17169459] 
Mellott et al. Page 22













51. Godbey WT, Mikos AG. Recent progress in gene delivery using non-viral transfer complexes. J 
Control Release. 2001; 72:115–25. [PubMed: 11389990] 
52. Godbey WT, Wu KK, Mikos AG. Poly(ethylenimine) and its role in gene delivery. J Control 
Release. 1999; 60:149–60. [PubMed: 10425321] 
53. Godbey WT, Wu KK, Mikos AG. Poly(ethylenimine)-mediated gene delivery affects endothelial 
cell function and viability. Biomaterials. 2001; 22:471–80. [PubMed: 11214758] 
54. Godbey WT, Wu KK, Mikos AG. Tracking the intracellular path of poly(ethylenimine)/DNA 
complexes for gene delivery. Proc Natl Acad Sci U S A. 1999; 96:5177–81. [PubMed: 10220439] 
55. Golzio M, Escoffre JM, Portet T, Mauroy C, Teissie J, Dean DS, Rols MP. Observations of the 
mechanisms of electromediated DNA uptake--from vesicles to tissues. Curr Gene Ther. 2010; 
10:256–66. [PubMed: 20557287] 
56. Golzio M, Mazeres S, Teissie J. Electrodes for in vivo localised subcutaneous electropulsation and 
associated drug and nucleic acid delivery. Expert Opin Drug Deliv. 2009; 6:1323–31. [PubMed: 
19860535] 
57. Golzio M, Rols MP, Gabriel B, Teissie J. Optical imaging of in vivo gene expression: a critical 
assessment of the methodology and associated technologies. Gene Ther. 2004; 11(Suppl 1):S85–
91. [PubMed: 15454962] 
58. Golzio M, Teissie J, Rols MP. Direct visualization at the single-cell level of electrically mediated 
gene delivery. Proc Natl Acad Sci U S A. 2002; 99:1292–7. [PubMed: 11818537] 
59. Gonzalez F, Barragan Monasterio M, Tiscornia G, Montserrat Pulido N, Vassena R, Batlle Morera 
L, Rodriguez Piza I, Izpisua Belmonte JC. Generation of mouse-induced pluripotent stem cells by 
transient expression of a single nonviral polycistronic vector. Proc Natl Acad Sci U S A. 2009; 
106:8918–22. [PubMed: 19458047] 
60. Green JJ, Chiu E, Leshchiner ES, Shi J, Langer R, Anderson DG. Electrostatic ligand coatings of 
nanoparticles enable ligand-specific gene delivery to human primary cells. Nano Lett. 2007; 
7:874–9. [PubMed: 17362046] 
61. Green JJ, Langer R, Anderson DG. A Combinatorial Polymer Library Approach Yields Insight into 
Nonviral Gene Delivery. Acc Chem Res. 2008
62. Green JJ, Shi J, Chiu E, Leshchiner ES, Langer R, Anderson DG. Biodegradable polymeric vectors 
for gene delivery to human endothelial cells. Bioconjug Chem. 2006; 17:1162–9. [PubMed: 
16984124] 
63. Green JJ, Zhou BY, Mitalipova MM, Beard C, Langer R, Jaenisch R, Anderson DG. Nanoparticles 
for gene transfer to human embryonic stem cell colonies. Nano Lett. 2008; 8:3126–30. [PubMed: 
18754690] 
64. Gwak SJ, Kim BS. Poly(lactic-co-glycolic acid) nanosphere as a vehicle for gene delivery to 
human cord blood-derived mesenchymal stem cells: comparison with polyethylenimine. 
Biotechnol Lett. 2008; 30:1177–82. [PubMed: 18317698] 
65. Haberl S, Miklavcic D, Pavlin M. Effect of Mg ions on efficiency of gene electrotransfer and on 
cell electropermeabilization. Bioelectrochemistry. 2010; 79:265–71. [PubMed: 20580903] 
66. Hay JC. Calcium: a fundamental regulator of intracellular membrane fusion? EMBO Rep. 2007; 
8:236–40. [PubMed: 17330068] 
67. He CX, Tabata Y, Gao JQ. Non-viral gene delivery carrier and its three-dimensional transfection 
system. Int J Pharm. 2010; 386:232–42. [PubMed: 19922780] 
68. Heller LC, Heller R. In vivo electroporation for gene therapy. Hum Gene Ther. 2006; 17:890–7. 
[PubMed: 16972757] 
69. Heller R, Jaroszeski M, Atkin A, Moradpour D, Gilbert R, Wands J, Nicolau C. In vivo gene 
electroinjection and expression in rat liver. FEBS Lett. 1996; 389:225–8. [PubMed: 8766704] 
70. Henshaw J, Mossop B, Yuan F. Enhancement of electric field-mediated gene delivery through 
pretreatment of tumors with a hyperosmotic mannitol solution. Cancer Gene Ther. 2011; 18:26–
33. [PubMed: 20847751] 
71. Henshaw JW, Yuan F. Field distribution and DNA transport in solid tumors during electric field-
mediated gene delivery. J Pharm Sci. 2008; 97:691–711. [PubMed: 17624918] 
72. Holladay CA, O’Brien T, Pandit A. Non-viral gene therapy for myocardial engineering. Wiley 
Interdiscip Rev Nanomed Nanobiotechnol. 2010; 2:232–48. [PubMed: 20063367] 
Mellott et al. Page 23













73. Huth S, Lausier J, Gersting SW, Rudolph C, Plank C, Welsch U, Rosenecker J. Insights into the 
mechanism of magnetofection using PEI-based magnetofectins for gene transfer. J Gene Med. 
2004; 6:923–36. [PubMed: 15293351] 
74. Hutson TH, Buchser WJ, Bixby JL, Lemmon VP, Moon LD. Optimization of a 96-Well 
Electroporation Assay for Postnatal Rat CNS Neurons Suitable for Cost-Effective Medium-
Throughput Screening of Genes that Promote Neurite Outgrowth. Front Mol Neurosci. 2011; 4:55. 
[PubMed: 22207835] 
75. Ino K, Kawasumi T, Ito A, Honda H. Plasmid DNA transfection using magnetite cationic 
liposomes for construction of multilayered gene-engineered cell sheet. Biotechnol Bioeng. 2008; 
100:168–76. [PubMed: 18078300] 
76. Jang JH, Houchin TL, Shea LD. Gene delivery from polymer scaffolds for tissue engineering. 
Expert Review of Medical Devices. 2004; 1:127–138. [PubMed: 16293016] 
77. Jang JH, Shea LD. Controllable delivery of non-viral DNA from porous scaffolds. J Control 
Release. 2003; 86:157–68. [PubMed: 12490381] 
78. Jo J, Tabata Y. Non-viral gene transfection technologies for genetic engineering of stem cells. Eur J 
Pharm Biopharm. 2008; 68:90–104. [PubMed: 17870447] 
79. Jordan ET, Collins M, Terefe J, Ugozzoli L, Rubio T. Optimizing electroporation conditions in 
primary and other difficult-to-transfect cells. J Biomol Tech. 2008; 19:328–34. [PubMed: 
19183796] 
80. Kaneda Y. Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery 
system with anticancer activities beyond delivery as a new therapeutic tool. Expert Opin Drug 
Deliv. 2010; 7:1079–93. [PubMed: 20716020] 
81. Kasper FK, Seidlits SK, Tang A, Crowther RS, Carney DH, Barry MA, Mikos AG. In vitro release 
of plasmid DNA from oligo(poly(ethylene glycol) fumarate) hydrogels. J Control Release. 2005; 
104:521–39. [PubMed: 15911051] 
82. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious 
agents into vehicles of therapeutics. Nat Med. 2001; 7:33–40. [PubMed: 11135613] 
83. Kendall M, Mitchell T, Wrighton-Smith P. Intradermal ballistic delivery of micro-particles into 
excised human skin for pharmaceutical applications. J Biomech. 2004; 37:1733–41. [PubMed: 
15388316] 
84. Kendall M, Rishworth S, Carter F, Mitchell T. Effects of relative humidity and ambient temperature 
on the ballistic delivery of micro-particles to excised porcine skin. J Invest Dermatol. 2004; 
122:739–46. [PubMed: 15086561] 
85. Kettunen P, Demas J, Lohmann C, Kasthuri N, Gong Y, Wong RO, Gan WB. Imaging calcium 
dynamics in the nervous system by means of ballistic delivery of indicators. J Neurosci Methods. 
2002; 119:37–43. [PubMed: 12234633] 
86. Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathways and subsequent intracellular 
trafficking in nonviral gene delivery. Pharmacol Rev. 2006; 58:32–45. [PubMed: 16507881] 
87. Khondee S, Baoum A, Siahaan TJ, Berkland C. Calcium condensed LABL-TAT complexes 
effectively target gene delivery to ICAM-1 expressing cells. Mol Pharm. 2011; 8:788–98. 
[PubMed: 21473630] 
88. Kirkham M, Parton RG. Clathrin-independent endocytosis: new insights into caveolae and non-
caveolar lipid raft carriers. Biochim Biophys Acta. 2005; 1746:349–63. [PubMed: 16440447] 
89. Kobayashi N, Rivas-Carrillo JD, Soto-Gutierrez A, Fukazawa T, Chen Y, Navarro-Alvarez N, 
Tanaka N. Gene delivery to embryonic stem cells. Birth Defects Res C Embryo Today. 2005; 
75:10–8. [PubMed: 15838919] 
90. Kofron MD, Laurencin CT. Bone tissue engineering by gene delivery. Adv Drug Deliv Rev. 2006; 
58:555–76. [PubMed: 16790291] 
91. Krotz F, Sohn HY, Gloe T, Plank C, Pohl U. Magnetofection potentiates gene delivery to cultured 
endothelial cells. J Vasc Res. 2003; 40:425–34. [PubMed: 14530599] 
92. Kucherlapati R, Skoultchi AI. Introduction of purified genes into mammalian cells. CRC Crit Rev 
Biochem. 1984; 16:349–79. [PubMed: 6094097] 
93. Kurata S, Tsukakoshi M, Kasuya T, Ikawa Y. The laser method for efficient introduction of foreign 
DNA into cultured cells. Exp Cell Res. 1986; 162:372–8. [PubMed: 3943549] 
Mellott et al. Page 24













94. Lamb NJ, Gauthier-Rouviere C, Fernandez A. Microinjection strategies for the study of mitogenic 
signaling in mammalian cells. Front Biosci. 1996; 1:d19–29. [PubMed: 9159206] 
95. Langer R, Moses M. Biocompatible controlled release polymers for delivery of polypeptides and 
growth factors. J Cell Biochem. 1991; 45:340–5. [PubMed: 2045427] 
96. Leipzig ND, Athanasiou KA. Static compression of single chondrocytes catabolically modifies 
single-cell gene expression. Biophys J. 2008; 94:2412–22. [PubMed: 18065463] 
97. Liang D, Luu YK, Kim K, Hsiao BS, Hadjiargyrou M, Chu B. In vitro non-viral gene delivery with 
nanofibrous scaffolds. Nucleic Acids Res. 2005; 33:e170. [PubMed: 16269820] 
98. Liang HD, Tang J, Halliwell M. Sonoporation, drug delivery, and gene therapy. Proc Inst Mech 
Eng H. 2010; 224:343–61. [PubMed: 20349823] 
99. Lim SH, Liao IC, Leong KW. Nonviral gene delivery from nonwoven fibrous scaffolds fabricated 
by interfacial complexation of polyelectrolytes. Mol Ther. 2006; 13:1163–72. [PubMed: 
16497560] 
100. Lo H, Kadiyala S, Guggino SE, Leong KW. Poly(L-lactic acid) foams with cell seeding and 
controlled-release capacity. J Biomed Mater Res. 1996; 30:475–84. [PubMed: 8847355] 
101. Lohr F, Lo DY, Zaharoff DA, Hu K, Zhang X, Li Y, Zhao Y, Dewhirst MW, Yuan F, Li CY. 
Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. 
Cancer Res. 2001; 61:3281–4. [PubMed: 11309280] 
102. Long X, Xiong SD, Xiong WN, Xu YJ. Effect of intramuscular injection of hepatocyte growth 
factor plasmid DNA with electroporation on bleomycin-induced lung fibrosis in rats. Chin Med J 
(Engl). 2007; 120:1432–7. [PubMed: 17825173] 
103. Lukacs GL, Haggie P, Seksek O, Lechardeur D, Freedman N, Verkman AS. Size-dependent DNA 
mobility in cytoplasm and nucleus. J Biol Chem. 2000; 275:1625–9. [PubMed: 10636854] 
104. Marine S, Freeman J, Riccio A, Axenborg ML, Pihl J, Ketteler R, Aspengren S. High-throughput 
transfection of differentiated primary neurons from rat forebrain. J Biomol Screen. 2012; 17:692–
6. [PubMed: 22403411] 
105. Mark Saltzman W, Baldwin SP. Materials for protein delivery in tissue engineering. Adv Drug 
Deliv Rev. 1998; 33:71–86. [PubMed: 10837654] 
106. Martinek V, Fu FH, Huard J. Gene therapy and tissue engineering in sports medicine. Phys 
Sportsmed. 2000; 28:34–51. [PubMed: 20086620] 
107. McCall J, Nicholson L, Weidner N, Blesch A. Optimization of adult sensory neuron 
electroporation to study mechanisms of neurite growth. Front Mol Neurosci. 2012; 5:11. 
[PubMed: 22347167] 
108. Mehier-Humbert S, Guy RH. Physical methods for gene transfer: improving the kinetics of gene 
delivery into cells. Adv Drug Deliv Rev. 2005; 57:733–53. [PubMed: 15757758] 
109. Mercer J, Schelhaas M, Helenius A. Virus entry by endocytosis. Annu Rev Biochem. 2010; 
79:803–33. [PubMed: 20196649] 
110. Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide 
therapy against cancer. Adv Drug Deliv Rev. 2002; 54:715–58. [PubMed: 12204600] 
111. Merkerova M, Klamova H, Brdicka R, Bruchova H. Targeting of gene expression by siRNA in 
CML primary cells. Mol Biol Rep. 2007; 34:27–33. [PubMed: 17094012] 
112. Middaugh CR, Ramsey JD. Analysis of cationic-lipid-plasmid-DNA complexes. Anal Chem. 
2007; 79:7240–8. [PubMed: 17972398] 
113. Midoux P, Pichon C, Yaouanc JJ, Jaffres PA. Chemical vectors for gene delivery: a current review 
on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br J 
Pharmacol. 2009; 157:166–78. [PubMed: 19459843] 
114. Mir LM. Nucleic acids electrotransfer-based gene therapy (electrogenetherapy): past, current, and 
future. Mol Biotechnol. 2009; 43:167–76. [PubMed: 19562526] 
115. Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM, Delaere P, Branellec D, Schwartz 
B, Scherman D. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. 
Proc Natl Acad Sci U S A. 1999; 96:4262–7. [PubMed: 10200250] 
116. Mitchell TJ, Kendall MAF, Bellhouse BJ. A ballistic study of micro-particle penetration to the 
oral mucosa. International journal of impact engineering. 2003; 28:581–599.
Mellott et al. Page 25













117. Mo D, Potter BA, Bertrand CA, Hildebrand JD, Bruns JR, Weisz OA. Nucleofection disrupts tight 
junction fence function to alter membrane polarity of renal epithelial cells. Am J Physiol Renal 
Physiol. 2010; 299:F1178–84. [PubMed: 20702601] 
118. Moore JC, Atze K, Yeung PL, Toro-Ramos AJ, Camarillo C, Thompson K, Ricupero CL, 
Brenneman MA, Cohen RI, Hart RP. Efficient, high-throughput transfection of human embryonic 
stem cells. Stem Cell Res Ther. 2010; 1:23. [PubMed: 20659329] 
119. Motoyama H, Ogawa S, Kubo A, Miwa S, Nakayama J, Tagawa Y, Miyagawa S. In vitro 
reprogramming of adult hepatocytes into insulin-producing cells without viral vectors. Biochem 
Biophys Res Commun. 2009; 385:123–8. [PubMed: 19422803] 
120. Nabi IR, Le PU. Caveolae/raft-dependent endocytosis. J Cell Biol. 2003; 161:673–7. [PubMed: 
12771123] 
121. Nathwani AC, Gale KM, Pemberton KD, Crossman DC, Tuddenham EG, McVey JH. Efficient 
gene transfer into human umbilical vein endothelial cells allows functional analysis of the human 
tissue factor gene promoter. Br J Haematol. 1994; 88:122–8. [PubMed: 7803234] 
122. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly 
in interstitial transport in solid tumors. Cancer Res. 2000; 60:2497–503. [PubMed: 10811131] 
123. Neu WK, Neu JC. Mechanism of Irreversible Electroporation in Cells: Insight from the Models. 
Irreversible Electroporation. 2010:85–122.
124. Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lyoma 
cells by electroporation in high electric fields. EMBO J. 1982; 1:841–5. [PubMed: 6329708] 
125. Newman CM, Bettinger T. Gene therapy progress and prospects: ultrasound for gene transfer. 
Gene Ther. 2007; 14:465–75. [PubMed: 17339881] 
126. Nie H, Wang CH. Fabrication and characterization of PLGA/HAp composite scaffolds for 
delivery of BMP-2 plasmid DNA. J Control Release. 2007; 120:111–21. [PubMed: 17512077] 
127. Nomikou N, McHale AP. Exploiting ultrasound-mediated effects in delivering targeted, site-
specific cancer therapy. Cancer Lett. 2010; 296:133–43. [PubMed: 20598800] 
128. O’Neill BE, Li KC. Augmentation of targeted delivery with pulsed high intensity focused 
ultrasound. Int J Hyperthermia. 2008; 24:506–20. [PubMed: 18608574] 
129. Ogura M, Sato S, Nakanishi K, Uenoyama M, Kiyozumi T, Saitoh D, Ikeda T, Ashida H, Obara 
M. In vivo targeted gene transfer in skin by the use of laser-induced stress waves. Lasers Surg 
Med. 2004; 34:242–8. [PubMed: 15022251] 
130. Palumbo G, Caruso M, Crescenzi E, Tecce MF, Roberti G, Colasanti A. Targeted gene transfer in 
eucaryotic cells by dye-assisted laser optoporation. J Photochem Photobiol B. 1996; 36:41–6. 
[PubMed: 8988610] 
131. Park JH, Allen MG, Prausnitz MR. Biodegradable polymer microneedles: fabrication, mechanics 
and transdermal drug delivery. J Control Release. 2005; 104:51–66. [PubMed: 15866334] 
132. Park TG, Jeong JH, Kim SW. Current status of polymeric gene delivery systems. Adv Drug Deliv 
Rev. 2006; 58:467–86. [PubMed: 16781003] 
133. Partridge KA, Oreffo RO. Gene delivery in bone tissue engineering: progress and prospects using 
viral and nonviral strategies. Tissue Eng. 2004; 10:295–307. [PubMed: 15009954] 
134. Pearton M, Allender C, Brain K, Anstey A, Gateley C, Wilke N, Morrissey A, Birchall J. Gene 
delivery to the epidermal cells of human skin explants using microfabricated microneedles and 
hydrogel formulations. Pharm Res. 2008; 25:407–16. [PubMed: 17671832] 
135. Pederson T. Movement and localization of RNA in the cell nucleus. FASEB J. 1999; 13(Suppl 
2):S238–42. [PubMed: 10619135] 
136. Phez E, Faurie C, Golzio M, Teissie J, Rols MP. New insights in the visualization of membrane 
permeabilization and DNA/membrane interaction of cells submitted to electric pulses. Biochim 
Biophys Acta. 2005; 1724:248–54. [PubMed: 15878640] 
137. Pickard MR, Barraud P, Chari DM. The transfection of multipotent neural precursor/stem cell 
transplant populations with magnetic nanoparticles. Biomaterials. 2011; 32:2274–84. [PubMed: 
21193228] 
138. Pimpha N, Sunintaboon P, Inphonlek S, Tabata Y. Gene delivery efficacy of polyethyleneimine-
introduced chitosan shell/poly(methyl methacrylate) core nanoparticles for rat mesenchymal stem 
cells. J Biomater Sci Polym Ed. 2010; 21:205–23. [PubMed: 20092685] 
Mellott et al. Page 26













139. Plank C, Anton M, Rudolph C, Rosenecker J, Krotz F. Enhancing and targeting nucleic acid 
delivery by magnetic force. Expert Opin Biol Ther. 2003; 3:745–58. [PubMed: 12880375] 
140. Plank C, Schillinger U, Scherer F, Bergemann C, Remy JS, Krotz F, Anton M, Lausier J, 
Rosenecker J. The magnetofection method: using magnetic force to enhance gene delivery. Biol 
Chem. 2003; 384:737–47. [PubMed: 12817470] 
141. Plank C, Zelphati O, Mykhaylyk O. Magnetically enhanced nucleic acid delivery. Ten years of 
magnetofection-progress and prospects. Adv Drug Deliv Rev. 2011; 63:1300–31. [PubMed: 
21893135] 
142. Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, di Tomaso E, Brown EB, Izumi Y, 
Campbell RB, Berk DA, Jain RK. Role of tumor-host interactions in interstitial diffusion of 
macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A. 2001; 98:4628–33. 
[PubMed: 11274375] 
143. Postema M, Gilja OH. Ultrasound-directed drug delivery. Curr Pharm Biotechnol. 2007; 8:355–
61. [PubMed: 18289044] 
144. Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev. 2004; 56:581–7. 
[PubMed: 15019747] 
145. Prausnitz MR, Corbett JD, Gimm JA, Golan DE, Langer R, Weaver JC. Millisecond measurement 
of transport during and after an electroporation pulse. Biophys J. 1995; 68:1864–70. [PubMed: 
7612828] 
146. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008; 26:1261–8. [PubMed: 
18997767] 
147. Ramos C, Teissie J. Electrofusion: a biophysical modification of cell membrane and a mechanism 
in exocytosis. Biochimie. 2000; 82:511–8. [PubMed: 10865136] 
148. Rejman J, Bragonzi A, Conese M. Role of clathrin- and caveolae-mediated endocytosis in gene 
transfer mediated by lipo- and polyplexes. Mol Ther. 2005; 12:468–74. [PubMed: 15963763] 
149. Rols MP, Delteil C, Golzio M, Dumond P, Cros S, Teissie J. In vivo electrically mediated protein 
and gene transfer in murine melanoma. Nat Biotechnol. 1998; 16:168–71. [PubMed: 9487524] 
150. Rols MP, Femenia P, Teissie J. Long-lived macropinocytosis takes place in electropermeabilized 
mammalian cells. Biochem Biophys Res Commun. 1995; 208:26–35. [PubMed: 7887937] 
151. Russell SJ. Science, medicine, and the future. Gene therapy. BMJ. 1997; 315:1289–92. [PubMed: 
9390059] 
152. Sagi S, Knoll T, Trojan L, Schaaf A, Alken P, Michel MS. Gene delivery into prostate cancer cells 
by holmium laser application. Prostate Cancer Prostatic Dis. 2003; 6:127–30. [PubMed: 
12806370] 
153. Saijilafu, Hur EM, Zhou FQ. Genetic dissection of axon regeneration via in vivo electroporation 
of adult mouse sensory neurons. Nat Commun. 2011; 2:543. [PubMed: 22109517] 
154. Sanford JC, THEODORE MK, EDWARD D, Allen N. Delivery of substances into cells and 
tissues using a particle bombardment process. Particulate Science and Technology. 1987; 5:27–
37.
155. Sapet C, Laurent N, de Chevigny A, Le Gourrierec L, Bertosio E, Zelphati O, Beclin C. High 
transfection efficiency of neural stem cells with magnetofection. Biotechniques. 2011; 50:187–9. 
[PubMed: 21486240] 
156. Saraf A, Mikos AG. Gene delivery strategies for cartilage tissue engineering. Adv Drug Deliv 
Rev. 2006; 58:592–603. [PubMed: 16766079] 
157. Satkauskas S, Bureau MF, Mahfoudi A, Mir LM. Slow accumulation of plasmid in muscle cells: 
supporting evidence for a mechanism of DNA uptake by receptor-mediated endocytosis. Mol 
Ther. 2001; 4:317–23. [PubMed: 11592834] 
158. Saul JM, Linnes MP, Ratner BD, Giachelli CM, Pun SH. Delivery of non-viral gene carriers from 
sphere-templated fibrin scaffolds for sustained transgene expression. Biomaterials. 2007; 
28:4705–16. [PubMed: 17675152] 
159. Saurer EM, Flessner RM, Sullivan SP, Prausnitz MR, Lynn DM. Layer-by-Layer Assembly of 
DNA- and Protein-Containing Films on Microneedles for Drug Delivery to the Skin. 
Biomacromolecules. 2010
Mellott et al. Page 27













160. Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Kruger A, Gansbacher B, Plank C. 
Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. 
Gene Ther. 2002; 9:102–9. [PubMed: 11857068] 
161. Schnoor M, Buers I, Sietmann A, Brodde MF, Hofnagel O, Robenek H, Lorkowski S. Efficient 
non-viral transfection of THP-1 cells. J Immunol Methods. 2009; 344:109–15. [PubMed: 
19345690] 
162. Schwachtgen JL, Ferreira V, Meyer D, Kerbiriou-Nabias D. Optimization of the transfection of 
human endothelial cells by electroporation. Biotechniques. 1994; 17:882–7. [PubMed: 7840968] 
163. Schwerdt JI, Goya GF, Calatayud MP, Herenu CB, Reggiani PC, Goya RG. Magnetic field-
assisted gene delivery: achievements and therapeutic potential. Curr Gene Ther. 2012; 12:116–
26. [PubMed: 22348552] 
164. Sersa G, Cemazar M, Parkins CS, Chaplin DJ. Tumour blood flow changes induced by 
application of electric pulses. Eur J Cancer. 1999; 35:672–7. [PubMed: 10492645] 
165. Sersa G, Jarm T, Kotnik T, Coer A, Podkrajsek M, Sentjurc M, Miklavcic D, Kadivec M, Kranjc 
S, Secerov A, Cemazar M. Vascular disrupting action of electroporation and electrochemotherapy 
with bleomycin in murine sarcoma. Br J Cancer. 2008; 98:388–98. [PubMed: 18182988] 
166. Sheyn D, Pelled G, Zilberman Y, Talasazan F, Frank JM, Gazit D, Gazit Z. Nonvirally engineered 
porcine adipose tissue-derived stem cells: use in posterior spinal fusion. Stem Cells. 2008; 
26:1056–64. [PubMed: 18218819] 
167. Shirahata Y, Ohkohchi N, Itagak H, Satomi S. New technique for gene transfection using laser 
irradiation. J Investig Med. 2001; 49:184–90.
168. Smith RL, Lin J, Trindade MC, Shida J, Kajiyama G, Vu T, Hoffman AR, van der Meulen MC, 
Goodman SB, Schurman DJ, Carter DR. Time-dependent effects of intermittent hydrostatic 
pressure on articular chondrocyte type II collagen and aggrecan mRNA expression. J Rehabil Res 
Dev. 2000; 37:153–61. [PubMed: 10850821] 
169. Sohn RL, Murray MT, Schwarz K, Nyitray J, Purray P, Franko AP, Palmer KC, Diebel LN, 
Dulchavsky SA. In-vivo particle mediated delivery of mRNA to mammalian tissues: ballistic and 
biologic effects. Wound Repair Regen. 2001; 9:287–96. [PubMed: 11679137] 
170. Song L, Chau L, Sakamoto Y, Nakashima J, Koide M, Tuan RS. Electric field-induced molecular 
vibration for noninvasive, high-efficiency DNA transfection. Mol Ther. 2004; 9:607–16. 
[PubMed: 15093191] 
171. Storrie H, Mooney DJ. Sustained delivery of plasmid DNA from polymeric scaffolds for tissue 
engineering. Adv Drug Deliv Rev. 2006; 58:500–14. [PubMed: 16759734] 
172. Tao W, Wilkinson J, Stanbridge EJ, Berns MW. Direct gene transfer into human cultured cells 
facilitated by laser micropuncture of the cell membrane. Proc Natl Acad Sci U S A. 1987; 
84:4180–4. [PubMed: 3473500] 
173. Teifel M, Heine LT, Milbredt S, Friedl P. Optimization of transfection of human endothelial cells. 
Endothelium. 1997; 5:21–35. [PubMed: 9142319] 
174. Teissie J, Golzio M, Rols MP. Mechanisms of cell membrane electropermeabilization: a 
minireview of our present (lack of ?) knowledge. Biochim Biophys Acta. 2005; 1724:270–80. 
[PubMed: 15951114] 
175. ter Haar G. Therapeutic applications of ultrasound. Prog Biophys Mol Biol. 2007; 93:111–29. 
[PubMed: 16930682] 
176. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene 
therapy. Nat Rev Genet. 2003; 4:346–58. [PubMed: 12728277] 
177. Udvardi A, Kufferath I, Grutsch H, Zatloukal K, Volc-Platzer B. Uptake of exogenous DNA via 
the skin. J Mol Med (Berl). 1999; 77:744–50. [PubMed: 10606210] 
178. van der Aa MA, Huth US, Hafele SY, Schubert R, Oosting RS, Mastrobattista E, Hennink WE, 
Peschka-Suss R, Koning GA, Crommelin DJ. Cellular uptake of cationic polymer-DNA 
complexes via caveolae plays a pivotal role in gene transfection in COS-7 cells. Pharm Res. 
2007; 24:1590–8. [PubMed: 17385010] 
179. Vaughan EE, Dean DA. Intracellular trafficking of plasmids during transfection is mediated by 
microtubules. Mol Ther. 2006; 13:422–8. [PubMed: 16301002] 
Mellott et al. Page 28













180. Verreault M, Bally MB. siRNA-mediated integrin-linked kinase suppression: nonspecific effects 
of siRNA/cationic liposome complexes trigger changes in the expression of phosphorylated-AKT 
and mTOR independently of ILK silencing. Oligonucleotides. 2009; 19:129–40. [PubMed: 
19284309] 
181. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev 
Genet. 2007; 8:573–87. [PubMed: 17607305] 
182. Walton JR, Murray JD, Marshall JT, Nancarrow CD. Zygote viability in gene transfer 
experiments. Biol Reprod. 1987; 37:957–67. [PubMed: 3689859] 
183. Wang L, Ott L, Seshareddy K, Weiss ML, Detamore MS. Musculoskeletal tissue engineering with 
human umbilical cord mesenchymal stromal cells. Regen Med. 2011; 6:95–109. [PubMed: 
21175290] 
184. Weaver JC. Electroporation: a general phenomenon for manipulating cells and tissues. J Cell 
Biochem. 1993; 51:426–35. [PubMed: 8496245] 
185. Weaver JC, Chizmadzhev YA. Theory of electroporation: a review. Bioelectrochemistry and 
Bioenergetics. 1996; 41:135–160.
186. Wells JM, Li LH, Sen A, Jahreis GP, Hui SW. Electroporation-enhanced gene delivery in 
mammary tumors. Gene Ther. 2000; 7:541–7. [PubMed: 10819568] 
187. Wiethoff CM, Middaugh CR. Barriers to nonviral gene delivery. J Pharm Sci. 2003; 92:203–17. 
[PubMed: 12532370] 
188. Williams SK, Wagner RC. Regulation of micropinocytosis in capillary endothelium by 
multivalent cations. Microvasc Res. 1981; 21:175–82. [PubMed: 6783813] 
189. Wu J. Shear stress in cells generated by ultrasound. Prog Biophys Mol Biol. 2007; 93:363–73. 
[PubMed: 16928394] 
190. Wu M, Yuan F. Membrane binding of plasmid DNA and endocytic pathways are involved in 
electrotransfection of mammalian cells. PloS one. 2011; 6:e20923. [PubMed: 21695134] 
191. Xie TD, Tsong TY. Study of mechanisms of electric field-induced DNA transfection. V. Effects of 
DNA topology on surface binding, cell uptake, expression, and integration into host 
chromosomes of DNA in the mammalian cell. Biophys J. 1993; 65:1684–9. [PubMed: 8274656] 
192. Xu Y, Szoka FC Jr . Mechanism of DNA release from cationic liposome/DNA complexes used in 
cell transfection. Biochemistry. 1996; 35:5616–23. [PubMed: 8639519] 
193. Yamamoto F, Furusawa M, Furusawa I, Obinata M. The ‘pricking’ method. A new efficient 
technique for mechanically introducing foreign DNA into the nuclei of culture cells. Exp Cell 
Res. 1982; 142:79–84. [PubMed: 6958471] 
194. Yang C, Cheng K, Weng W. Immobilization of RGD peptide on HA coating through a chemical 
bonding approach. J Mater Sci Mater Med. 2009
195. Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to 
mammalian somatic cells by particle bombardment. Proc Natl Acad Sci U S A. 1990; 87:9568–
72. [PubMed: 2175906] 
196. Yang SY, Sun JS, Liu CH, Tsuang YH, Chen LT, Hong CY, Yang HC, Horng HE. Ex vivo 
magnetofection with magnetic nanoparticles: a novel platform for nonviral tissue engineering. 
Artif Organs. 2008; 32:195–204. [PubMed: 18201284] 
197. Yao CP, Zhang ZX, Rahmanzadeh R, Huettmann G. Laser-based gene transfection and gene 
therapy. IEEE Trans Nanobioscience. 2008; 7:111–9. [PubMed: 18556259] 
198. Yockell-Lelievre J, Riendeau V, Gagnon SN, Garenc C, Audette M. Efficient transfection of 
endothelial cells by a double-pulse electroporation method. DNA Cell Biol. 2009; 28:561–6. 
[PubMed: 19630533] 
199. Yoon CS, Park JH. Ultrasound-mediated gene delivery. Expert Opin Drug Deliv. 2010; 7:321–30. 
[PubMed: 20166854] 
200. Zaharoff DA, Henshaw JW, Mossop B, Yuan F. Mechanistic analysis of electroporation-induced 
cellular uptake of macromolecules. Exp Biol Med (Maywood). 2008; 233:94–105. [PubMed: 
18156311] 
201. Zefirov AL, Abdrakhmanov MM, Mukhamedyarov MA, Grigoryev PN. The role of extracellular 
calcium in exo- and endocytosis of synaptic vesicles at the frog motor nerve terminals. 
Neuroscience. 2006; 143:905–10. [PubMed: 17000054] 
Mellott et al. Page 29













202. Zeira E, Manevitch A, Khatchatouriants A, Pappo O, Hyam E, Darash-Yahana M, Tavor E, 
Honigman A, Lewis A, Galun E. Femtosecond infrared laser-an efficient and safe in vivo gene 
delivery system for prolonged expression. Mol Ther. 2003; 8:342–50. [PubMed: 12907157] 
203. Zelenin AV, Kolesnikov VA, Tarasenko OA, Shafei RA, Zelenina IA, Mikhailov VV, Semenova 
ML, Kovalenko DV, Artemyeva OV, Ivaschenko TE, Evgrafov OV, Dickson G, Baranovand VS. 
Bacterial beta-galactosidase and human dystrophin genes are expressed in mouse skeletal muscle 
fibers after ballistic transfection. FEBS Lett. 1997; 414:319–22. [PubMed: 9315710] 
204. Zelphati O, Szoka FC Jr . Mechanism of oligonucleotide release from cationic liposomes. Proc 
Natl Acad Sci U S A. 1996; 93:11493–8. [PubMed: 8876163] 
205. Zhang X, Godbey WT. Viral vectors for gene delivery in tissue engineering. Adv Drug Deliv Rev. 
2006; 58:515–34. [PubMed: 16762441] 
206. Zhang Z, Slobodianski A, Ito WD, Arnold A, Nehlsen J, Weng S, Lund N, Liu J, Egana JT, 
Lohmeyer JA, Muller DF, Machens HG. Enhanced collateral growth by double transplantation of 
gene-nucleofected fibroblasts in ischemic hindlimb of rats. PloS one. 2011; 6:e19192. [PubMed: 
21547081] 
207. Zhou Y, Shi J, Cui J, Deng CX. Effects of extracellular calcium on cell membrane resealing in 
sonoporation. J Control Release. 2008; 126:34–43. [PubMed: 18158198] 
208. Zimmermann U. Electric field-mediated fusion and related electrical phenomena. Biochim 
Biophys Acta. 1982; 694:227–77. [PubMed: 6758848] 
Mellott et al. Page 30













Figure 1. Gene Delivery Barriers
DNA must overcome several barriers during the delivery process to successfully produce 
desired gene expression. The green arrows are the pathway DNA must follow to induce gene 
expression, while the red arrows indicate potential barriers that prevent gene delivery. 1) 
DNA must avoid extracellular nucleases and 2) DNA must associate with the cellular 
membrane in some form to gain access to the cell via penetration, electrostatic interactions, 
adsorption, or ligand mediated receptor binding. DNA that enters through endocytosis must 
escape the endosome before the endosome 3) is recycled back to the cell membrane or 4) 
before the endosome matures into a lysosome, and DNA is degraded. In the cytoplasmic 
compartment, DNA must traffic toward the nuclear envelope and 5) avoid degradation by 
intracellular nucleases. Finally, to produce gene expression, 6) DNA must cross the nuclear 
envelope by transport through a nuclear pore (non-dividing cells) or passively re-locate into 
the nucleus between the disassembly and reformation of the nuclear envelope during mitosis 
(dividing cells). Gene expression is produced when enough intact DNA is transcribed in the 
nucleus into mRNA, and then translated into a protein, composed of amino acids, in the 
cytoplasm.
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Microinjection strategies utilize microneedles to deliver DNA directly to cell nuclei. A) In 
traditional microinjection, an individual cell is held in place by the tip of a pipette while a 
technician uses a microscope to pierce the cell membrane and nuclear envelope with a 
microneedle to deliver genetic material to the cell nucleus. B) Microneedles can be 
fabricated so that the shaft is hollow and able to carry a suspension of genetic material for 
injection, or microneedles can be fabricated so that the shaft is solid and the tip is dipped in 
a suspension of genetic material for application to tissues via coating or scratching. C) 
Microneedles can be arranged in arrays on patches that can be applied directly to the skin. 
The microneedle patches are capable of penetrating the stratum corneum and delivering 
drugs or genetic material to the epidermal tissues.
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Figure 3. Ballistic Gene Delivery
Plasmid DNA is mixed with gold or tungsten particles ranging in size from nanometers to 
micrometers. An electric or plasma discharge is used to propel the DNA/particle complexes 
into tissues or cell cultures.
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Electroporation strategies apply a current across cells or tissues to make cell membranes 
more permeable to exogenous DNA. A) Traditional electroporators have a pulse generator 
and a pair of electrodes that can be applied directly to tissues or cells. A cuvette utilizes plate 
electrodes to apply a voltage potential across cells in suspension. Since resistance is 
constant, the current is proportional to the voltage potential. As voltage reaches a critical 
threshold, hydrophilic pores form in the cell membrane make it permeable to plasmid DNA. 
The negatively charged DNA is mobile in the electrical field (toward the positive electrode) 
so DNA transport into permeabilized cells is greater than by diffusion alone. B) Needle 
electrodes have been used for in vivo applications where needles are inserted directly into 
primary tissues such as skin or skeletal muscle fibers after DNA has been injected. A current 
is applied across a very small area of tissue to facilitate the same process as in a cuvette.
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Ultrasonic frequencies are used to induce the cavitation of microbubbles for creating pores 
in cells contained in culture or tissue. The acoustic waves cause microbubbles to expand and 
then collapse. When the microbubbles collapse, a microshockwave is emitted that can 
rupture a cell membrane if the collapsing microbubble is in close proximity to the cell 
membrane. The ruptured cell membrane forms a pore, which allows cells to be temporarily 
more permeable to plasmid DNA.
Mellott et al. Page 35













Figure 6. Laser Induced Pore Formation
Pulsed lasers have been shown to perforate cell membranes similar to microinjection 
strategies, but without the use of a needle. Investigators have shown a variety of laser beams 
of varying wavelengths are capable of making precise “holes” in cell membranes when beam 
energy, pulse frequency, and exposure duration are manipulated. Investigators can precisely 
target individual cells in culture or in tissue with aid of a microscope to target specific sites 
on cells for perforation to allow DNA to enter cells. A second laser with an uninterrupted 
beam can be used to immobilize individual cells in suspension while a pulsed laser is used to 
perforate cells.
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